<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>552</serviceExecutionTime><Drug id="103031"><DrugName>rituximab biosimilar, Zhejiang Teruisi Pharmaceutical</DrugName><DrugNamesKey><Name id="42758398">rituximab</Name></DrugNamesKey><DrugSynonyms><Name><Value>rituximab</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>rituximab biosimilar, Zhejiang Teruisi Pharmaceutical</Value></Name><Name><Value>recombinant murine/human chimeric anti-CD20 monoclonal antibody, Teruisi Pharmaceutical</Value></Name><Name><Value>TRS-001</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1069890">Zhejiang Teruisi Pharmaceutical Inc</CompanyOriginator><CompaniesSecondary><Company id="1069890">Zhejiang Teruisi Pharmaceutical Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1069890" type="Company"><TargetEntity id="5037457141" type="organizationId">Zhejiang Teruisi Pharmaceutical Inc</TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"/><TargetEntity id="690" type="siCondition"/></SourceEntity><SourceEntity id="316" type="ciIndication"><TargetEntity id="10003899" type="MEDDRA"/><TargetEntity id="-1829786210" type="omicsDisease"/><TargetEntity id="699" type="siCondition"/></SourceEntity><SourceEntity id="PTGT-00379" type="ciTarget"><TargetEntity id="4436248919313" type="siTarget">B-lymphocyte antigen CD20</TargetEntity><TargetEntity id="-827076151" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="316">B-cell lymphoma</Indication></IndicationsSecondary><ActionsPrimary><Action id="5085">B-lymphocyte antigen CD20 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="55685">Anticancer monoclonal antibody</Action></ActionsSecondary><Technologies><Technology id="166">Chimeric monoclonal antibody</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="85">Protein recombinant</Technology><Technology id="962">Biosimilar product</Technology></Technologies><LastModificationDate>2019-06-07T08:06:32.000Z</LastModificationDate><ChangeDateLast>2019-06-07T00:00:00.000Z</ChangeDateLast><AddedDate>2016-08-05T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1069890" linkType="Company"&gt;Zhejiang Teruisi Pharmaceutical&lt;/ulink&gt; was  investigating TRS-001, a biosimilar version  of &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt;, a murine/human chimeric anti-CD20 monoclonal antibody (mAb), for the potential injectable treatment of B-cell lymphoma and chronic lymphocytic leukemia [&lt;ulink linkID="1785293" linkType="Reference"&gt;1785293&lt;/ulink&gt;]. In August 2016, a clinical trial application was filed in China [&lt;ulink linkID="1785293" linkType="Reference"&gt;1785293&lt;/ulink&gt;]. However, in May 2019, it was reported that the development of TRS-001had been discontinued, and the drug was used an intermediate for  &lt;ulink linkID="106693" linkType="Drug"&gt;TRS-005&lt;/ulink&gt; [&lt;ulink linkID="2155000" linkType="Reference"&gt;2155000&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In August 2016, the company was developing this mAb as a class 2 therapeutic biologic in China [&lt;ulink linkID="1785293" linkType="Reference"&gt;1785293&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2019, it was reported that the development of TRS-001 had been discontinued, and the drug was used an intermediate for  &lt;ulink linkID="106693" linkType="Drug"&gt;TRS-005&lt;/ulink&gt; [&lt;ulink linkID="2155000" linkType="Reference"&gt;2155000&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2016, a clinical trial application was filed in China [&lt;ulink linkID="1785293" linkType="Reference"&gt;1785293&lt;/ulink&gt;]; in July 2017, review of the application was concluded though the outcome was not published yet [&lt;ulink linkID="1945244" linkType="Reference"&gt;1945244&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1069890">Zhejiang Teruisi Pharmaceutical Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2019-05-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1069890">Zhejiang Teruisi Pharmaceutical Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="316">B-cell lymphoma</Indication><StatusDate>2019-05-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1069890">Zhejiang Teruisi Pharmaceutical Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2016-08-03T00:00:00.000Z</StatusDate><Source id="1785293" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1069890">Zhejiang Teruisi Pharmaceutical Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="316">B-cell lymphoma</Indication><StatusDate>2016-08-03T00:00:00.000Z</StatusDate><Source id="1785293" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00379"><Name>B-lymphocyte antigen CD20</Name><SwissprotNumbers><Swissprot>P11836</Swissprot><Swissprot>P19437</Swissprot><Swissprot>Q3C2E2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="4166807" number="WO-2018149413" title="CD20-targeted antibody coupling pharmaceutical preparation"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Teruisi Pharmaceutical Inc" id="1069890"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="13004"><DrugName>lagatide</DrugName><DrugNamesKey><Name id="42749863">lagatide</Name></DrugNamesKey><DrugSynonyms><Name><Value>BN-52080</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>lagatide</Value><Types><Type>INN</Type></Types></Name><Name><Value>peptides (diarrhea), Beaufour-Ipsen</Value></Name><Name><Value>157476-77-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17259">Ipsen</CompanyOriginator><CompaniesSecondary><Company id="17259">Ipsen</Company></CompaniesSecondary><CrossReferences><SourceEntity id="13004" type="Drug"><TargetEntity id="230976" type="siDrug">Lagatide</TargetEntity></SourceEntity><SourceEntity id="17259" type="Company"><TargetEntity id="4295868520" type="organizationId">Ipsen SA</TargetEntity></SourceEntity><SourceEntity id="102" type="ciIndication"><TargetEntity id="10012735" type="MEDDRA"/><TargetEntity id="D003967" type="MeSH"/><TargetEntity id="-957779542" type="omicsDisease"/><TargetEntity id="380" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="102">Diarrhea</Indication></IndicationsSecondary><ActionsSecondary><Action id="4007">Antidiarrhoeal</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology></Technologies><EphmraCodes><Ephmra><Code>A7</Code><Name>ANTIDIARRHOEALS, ORAL ELECTROLYTE REPLACERS AND INTESTINAL ANTI-INFLAMMATORIES</Name></Ephmra></EphmraCodes><LastModificationDate>2013-01-16T12:38:50.000Z</LastModificationDate><ChangeDateLast>2013-01-16T00:00:00.000Z</ChangeDateLast><AddedDate>1996-08-16T15:26:07.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="17259"&gt;Beaufour-Ipsen&lt;/ulink&gt; was developing lagatide (BN-520080), a heptapeptide sorbin analog and antisecretory agent, for the potential treatment of diarrhea [&lt;ulink linkType="reference" linkID="186386"&gt;186386&lt;/ulink&gt;]. By January 1998, the compound was  in phase II clinical trials for the treatment of diarrhea [&lt;ulink linkType="reference" linkID="312179"&gt;312179&lt;/ulink&gt;]; however, no further development has been reported. &lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17259">Ipsen</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1999-07-21T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="102">Diarrhea</Indication><Source id="186386" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17259">Ipsen</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1997-10-16T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="21844"><DrugName>interleukin modulators, Receptron</DrugName><DrugSynonyms><Name><Value>interleukin modulators, Receptron</Value></Name></DrugSynonyms><CompanyOriginator id="24733">Receptron Inc</CompanyOriginator><CompaniesSecondary><Company id="24733">Receptron Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="24733" type="Company"><TargetEntity id="4296849872" type="organizationId">Receptron Inc</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="910" type="Action"><TargetEntity id="2479" type="Mechanism">IL-4 Modulators</TargetEntity></SourceEntity><SourceEntity id="892" type="Action"><TargetEntity id="3055" type="Mechanism">IL-6 Modulators</TargetEntity></SourceEntity><SourceEntity id="924" type="Action"><TargetEntity id="6685" type="Mechanism">Interleukin 2 (IL-2) Modulators</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="31">Asthma</Indication></IndicationsSecondary><ActionsSecondary><Action id="892">IL-6 modulator</Action><Action id="2953">Anti-inflammatory</Action><Action id="910">IL-4 modulator</Action><Action id="924">IL-2 modulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2005-09-28T16:54:33.000Z</LastModificationDate><ChangeDateLast>2005-09-28T16:54:33.000Z</ChangeDateLast><AddedDate>1999-02-01T12:52:18.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="24733"&gt;Receptron&lt;/ulink&gt; was investigating modulators of interleukin 2, 4 and 6 for the potential treatment of asthma and inflammation [&lt;ulink linkType="reference" linkID="312999"&gt;312999&lt;/ulink&gt;].  However, no development has been reported since that time.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By January 1999, designs of screening assays for agonists or antagonists were underway [&lt;ulink linkType="reference" linkID="312999"&gt;312999&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt; &lt;/para&gt;&lt;para&gt; &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24733">Receptron Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2000-07-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24733">Receptron Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2000-07-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24733">Receptron Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>1999-01-18T00:00:00.000Z</StatusDate><Source id="312999" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24733">Receptron Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>1999-01-18T00:00:00.000Z</StatusDate><Source id="312999" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="29019"><DrugName>siderophore-beta-lactam conjugates, Grunenthal</DrugName><DrugSynonyms><Name><Value>HKI-9924129</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HKI-9724037</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HKI-9824091</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HKI-9824102</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HKI-9924047</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HKI-9924067</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HKI-9924109</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HKI-9924154</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HKI-9924155</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>siderophore-beta-lactam conjugates, Grunenthal</Value></Name></DrugSynonyms><CompanyOriginator id="16587">Grunenthal GmbH</CompanyOriginator><CompaniesSecondary><Company id="16587">Grunenthal GmbH</Company></CompaniesSecondary><CrossReferences><SourceEntity id="29019" type="Drug"><TargetEntity id="312949" type="siDrug">HKI-9924109</TargetEntity></SourceEntity><SourceEntity id="16587" type="Company"><TargetEntity id="4296790654" type="organizationId">Gruenenthal GmbH</TargetEntity></SourceEntity><SourceEntity id="137" type="ciIndication"><TargetEntity id="D016905" type="MeSH"/><TargetEntity id="-409642348" type="omicsDisease"/><TargetEntity id="801" type="siCondition"/></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="137">Gram negative bacterium infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="1535">Beta lactam antibiotic</Action><Action id="1594">Antibacterial</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="66">Antibiotic</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2014-04-22T12:01:05.000Z</LastModificationDate><ChangeDateLast>2010-05-04T15:01:26.000Z</ChangeDateLast><AddedDate>2000-06-06T17:00:06.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="16587"&gt;Grunenthal&lt;/ulink&gt; and researchers at the &lt;ulink linkType="Company" linkID="24984"&gt;Hans-Knoll Institut fuer Naturstoff-Forschung EV&lt;/ulink&gt; were investigating siderophore-beta-lactam conjugates, including HKI-9924129 and HKI-9924109 (structure shown), for the potential treatment of Gram-negative bacterial infections [&lt;ulink linkType="reference" linkID="369891"&gt;369891&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2005, preclinical data on HKI-9924109, HKI-9924154 and HKI-9924155 were presented at the 45th ICAAC meeting in Washington DC. The antibacterial properties  of these compounds were compared to ampicillin and amoxicillin, against a panel of 45 non-fermentative Gram-negative bacilli (NFGNB) and 41 Enterobacteriaceae. HKI-9924109 was the most active in the series, with MIC values of 8 ng/ml or less for 75% of NFGNBs and 44% of Enterobacteriaceae [&lt;ulink linkType="Reference" linkID="641458"&gt;641458&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="641780"&gt;641780&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2002, results were published on ampicillin and amoxicillin derivatives of N,N'-(2,3-diacetoxybenzoyl)-N-aminobutyl-glycine. HKI-9924154 and HKI-9924155 were shown to possess strong antibacterial activity. The MIC values for HKI-9924154 and HKI-9924155 against P aeruginos, E coli, K pneumoniae, S maltophilia, and S marcescens were in the range of 0.01 to &amp;lt; 0.005 mg/l [&lt;ulink linkType="reference" linkID="460038"&gt;460038&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2001, data on a series of acylaminopenicillins including HKI-9924129, were presented at the 41st ICAAC meeting in Chicago, IL. HKI-9924129 showed potent in vitro activity against standard enterobacterial strains particularly against S maltophilia, MIC50 values of less than 0.03 mg/l for HKI-9924129 compared to &amp;gt; 128 mg/l for ampicillin. The increased activity was mirrored in an in vivo testing with HKI-9924129, displaying an ED50 value of 10.42 mg/kg iv in a P aeruginosa ATCC 9027 murine infection model [&lt;ulink linkType="reference" linkID="433710"&gt;433710&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="421317"&gt;421317&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="421321"&gt;421321&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Siderophore mimetics were covalently bound to aminopenicillins and characterized with respect to their in vitro and in vivo activity and toxicology after iv administration to rodents. The conjugates were highly active at MICs generally below 10 mg/l. Bactericidal activity was time-dependent. Regrowth occurred at concentrations below the MICs after 6 h. In a mouse model of Pseudomonas aeruginosa septicemia, the effective dose for 50% survival was approximately 20 mg/kg/day after iv or sc administration. Conjugates were not mutagenic in the Ames test, micronucleus or comet assays. After single iv doses of 100 mg/kg to rodents, toxicological effects were seen which were not observed after administration of the unmodified beta-lactam. Toxicological findings after single iv administration to rats were correlated to the in vivo ED50 values, showing safety margins for HKI-9824102 &amp;gt; HKI-9824091 and HKI-9724037. In repeated dose toxicity studies in rats (iv 2 weeks), HKI-9724037 was tolerated best [&lt;ulink linkType="reference" linkID="369891"&gt;369891&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vitro activities (MIC range (mg/l)) against P vulgaris were: 1 to 2; 128 to &amp;gt; 256; and 2 to 4 for HKI-9824091, HKI-9824102 and HKI-9724037, respectively; against E coli were 0.5 to 128; 32 to &amp;gt; 256; 0.5 to 256, repectively; and, for S marcescens: 16  to &amp;gt; 256; 2  to &amp;gt; 256; and, 32 to &amp;gt; 256, respectively [&lt;ulink linkType="reference" linkID="369891"&gt;369891&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16587">Grunenthal GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2010-05-04T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="16587">Grunenthal GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="137">Gram negative bacterium infection</Indication><StatusDate>2000-06-06T00:00:00.000Z</StatusDate><Source id="369891" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="16587">Grunenthal GmbH</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24984">Hans Knoell Institute of Natural Products Research</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="130376" title="Hans-Knoll Institut to investigate siderophore-beta-lactam conjugates with Grunenthal"/></Deals><PatentFamilies><PatentFamily id="2027751" number="WO-02070017" title="Siderophore antibiotic conjugates with tetra- or hexadentate iron chelators on the basis of amino acids or peptides, method for producing them and the use thereof"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Grunenthal GmbH" id="16587"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="33291"><DrugName>AVP-26452</DrugName><DrugSynonyms><Name><Value>AVP-26452</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ApoA-1 hypolipidemics, AVANIR</Value></Name><Name><Value>apolipoprotein A1 hypolipidemics, AVANIR</Value></Name><Name><Value>AZD-2479</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17793">Avanir Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="14190">AstraZeneca plc</Company><Company id="17793">Avanir Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="33291" type="Drug"><TargetEntity id="363175" type="siDrug">AVP-26452</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="17793" type="Company"><TargetEntity id="5000013748" type="organizationId">Avanir Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="175" type="ciIndication"><TargetEntity id="10062060" type="MEDDRA"/><TargetEntity id="D006949" type="MeSH"/><TargetEntity id="-1908196798" type="omicsDisease"/><TargetEntity id="971" type="siCondition"/></SourceEntity><SourceEntity id="72" type="Action"><TargetEntity id="1052" type="Mechanism">Lipid Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="2621" type="Action"><TargetEntity id="5275" type="Mechanism">Drugs Targeting Apolipoproteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="175">Hyperlipidemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="2621">Apolipoprotein modulator</Action></ActionsPrimary><ActionsSecondary><Action id="72">Antihyperlipidemic agent</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C10</Code><Name>HYPOLIPIDAEMICS/ANTI-ATHEROMA PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-29T11:29:56.000Z</LastModificationDate><ChangeDateLast>2009-09-10T16:19:41.000Z</ChangeDateLast><AddedDate>2001-03-14T10:31:16.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="17793" linkType="Company"&gt;AVANIR&lt;/ulink&gt; was  developing  AVP-26452 (AZD-2479), the lead from a series of orally-active apolipoprotein A1 (ApoA-1) hypolipidemic agents, which enhance reverse cholesterol transport, for the potential treatment for hyperlipidemia [&lt;ulink linkID="615253" linkType="Reference"&gt;615253&lt;/ulink&gt;], [&lt;ulink linkID="615276" linkType="Reference"&gt;615276&lt;/ulink&gt;].   In January 2006, a phase I trial started [&lt;ulink linkID="643227" linkType="Reference"&gt;643227&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt; was collaborating with AVANIR for the development of this program, but ended the deal and returned full rights to the compounds in March 2007 [&lt;ulink linkID="779087" linkType="Reference"&gt;779087&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In January 2006, a phase I study started to evaluate the safety, tolerability and pharmacokinetics of AVP-26452. Healthy volunteers would be randomized to receive ascending single doses of the drug or placebo   [&lt;ulink linkID="643227" linkType="Reference"&gt;643227&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2004, AVANIR reported preclinical data which showed that the small molecules identified from this program reduced the plaque associated with atherosclerosis. There were also favorable effects on plasma cholesterol levels in lowering LDL cholesterol while increasing HDL cholesterol. The lead compound AVP-26452 demonstrated an ability to increase LDL-mediated cholesterol uptake in cultured human liver cells, thereby facilitating the hepatic clearance of LDL. It had also demonstrated an ability to decrease oxidized LDL-mediated cholesterol and cholesteryl ester accumulation in cultured human vascular smooth muscle. AVP-26452 had demonstrated an ability to decrease acetylated LDL-mediated cholesterol and cholesteryl ester accumulation in cultured human macrophages and appeared to promote cholesterol efflux from acetylated-LDL-loaded human macrophages. In vivo, AVP-26452 demonstrated an ability to inhibit foam cell formation. In atherosclerosis-prone ApoE-deficient mice, AVP-26452 lowered plasma cholesterol associated with LDL. Following oral administration over 10 weeks, aortas from mice treated with AVP-26452 showed dose-dependent reduction in fatty atherosclerotic plaques compared to placebo-treated control mice [&lt;ulink linkID="527284" linkType="reference"&gt;527284&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2005, AstraZeneca and AVANIR entered an alliance to discover and develop reverse cholesterol transport enhancing compounds [&lt;ulink linkID="615276" linkType="Reference"&gt;615276&lt;/ulink&gt;]. However, in March 2007, AstraZeneca returned all rights to AVANIR [&lt;ulink linkID="779087" linkType="Reference"&gt;779087&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;AVANIR targeted  the reverse cholesterol transport system via the HDL pathway [&lt;ulink linkID="401792" linkType="reference"&gt;401792&lt;/ulink&gt;], [&lt;ulink linkID="527284" linkType="reference"&gt;527284&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="175">Hyperlipidemia</Indication><StatusDate>2007-03-29T00:00:00.000Z</StatusDate><Source id="779087" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17793">Avanir Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2009-07-29T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17793">Avanir Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2001-03-14T00:00:00.000Z</StatusDate><Source id="401792" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2005-07-11T00:00:00.000Z</StatusDate><Source id="615276" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2006-01-03T00:00:00.000Z</StatusDate><Source id="643227" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17793">Avanir Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="175">Hyperlipidemia</Indication><StatusDate>2006-01-03T00:00:00.000Z</StatusDate><Source id="643227" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00143"><Name>Apolipoprotein</Name><SwissprotNumbers><Swissprot>P07095</Swissprot><Swissprot>P07096</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1040632">Otsuka Holdings Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="108072" title="AstraZeneca to develop AVANIR Pharmaceuticals's AVP-26452 and related compounds for cardiovascular disease  "/></Deals><PatentFamilies><PatentFamily id="1087215" number="WO-2007055873" title="Process for the manufacture of peptide facilitators of reverse cholesterol transport"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Otsuka Holdings Co Ltd" id="1040632"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="3365"><DrugName>Actimmune</DrugName><DrugNamesKey><Name id="42851783">Actimmune</Name><Name id="42765892">Imuforgamma</Name><Name id="43081403">Imukine</Name><Name id="42851785">interferon gamma-1b</Name></DrugNamesKey><DrugSynonyms><Name><Value>Imukin</Value></Name><Name><Value>Immukine</Value></Name><Name><Value>Imuforgamma</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>interferon (gamma1b), Toray</Value></Name><Name><Value>interferon gamma, Connetics</Value></Name><Name><Value>interferon (gamma1b), Daiichi</Value></Name><Name><Value>interferon (gamma1b), Genentech</Value></Name><Name><Value>interferon (gamma1b), Boehringer</Value></Name><Name><Value>interferon gamma, Connective Therapeutics</Value></Name><Name><Value>Actimmune</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Immukin</Value></Name><Name><Value>interferon gamma-1b</Value><Types><Type>USAN</Type><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>DasKloster 1001-01</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>DK-1001, mondoBIOTECH</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>DK-1001, THERAMetrics</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Imukine</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>interferon gamma-1b, Horizon/Clinigen</Value></Name></DrugSynonyms><CompanyOriginator id="19453">Genentech Inc</CompanyOriginator><CompaniesPrimary><Company id="1053335">Horizon Pharma plc</Company><Company id="1062207">Clinigen Group plc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1067362">Vidara Therapeutics LLC</Company><Company id="14881">Boehringer Ingelheim International GmbH</Company><Company id="15530">Connetics Corp</Company><Company id="19453">Genentech Inc</Company><Company id="24820">Maxygen LLC</Company><Company id="26430">InterMune Inc</Company><Company id="29586">Relief Therapeutics Holding AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="3365" type="Drug"><TargetEntity id="168624" type="siDrug">IFN-gamma-1b</TargetEntity></SourceEntity><SourceEntity id="1053335" type="Company"><TargetEntity id="5037276891" type="organizationId">Horizon Therapeutics PLC</TargetEntity></SourceEntity><SourceEntity id="1062207" type="Company"><TargetEntity id="5036225835" type="organizationId">Clinigen Group PLC</TargetEntity></SourceEntity><SourceEntity id="1067362" type="Company"><TargetEntity id="5037276902" type="organizationId">Vidara Therapeutics Holdings LLC</TargetEntity></SourceEntity><SourceEntity id="14881" type="Company"><TargetEntity id="4298428312" type="organizationId">Boehringer Ingelheim International GmbH</TargetEntity></SourceEntity><SourceEntity id="15530" type="Company"><TargetEntity id="4295906043" type="organizationId">Stiefel West Coast LLC</TargetEntity></SourceEntity><SourceEntity id="19453" type="Company"><TargetEntity id="4295912132" type="organizationId">Genentech Inc</TargetEntity></SourceEntity><SourceEntity id="24820" type="Company"><TargetEntity id="4295914134" type="organizationId">Maxygen Inc</TargetEntity></SourceEntity><SourceEntity id="26430" type="Company"><TargetEntity id="4295913836" type="organizationId">InterMune Inc</TargetEntity></SourceEntity><SourceEntity id="29586" type="Company"><TargetEntity id="5000098134" type="organizationId">RELIEF THERAPEUTICS Holding SA</TargetEntity></SourceEntity><SourceEntity id="1102" type="ciIndication"><TargetEntity id="L20" type="ICD10"/><TargetEntity id="691" type="ICD9"/><TargetEntity id="10012438" type="MEDDRA"/><TargetEntity id="D003876" type="MeSH"/><TargetEntity id="-1439185598" type="omicsDisease"/><TargetEntity id="456" type="siCondition"/></SourceEntity><SourceEntity id="124" type="ciIndication"><TargetEntity id="10017533" type="MEDDRA"/><TargetEntity id="D009181" type="MeSH"/><TargetEntity id="-2109353222" type="omicsDisease"/><TargetEntity id="817" type="siCondition"/></SourceEntity><SourceEntity id="1265" type="ciIndication"><TargetEntity id="Q78.2" type="ICD10"/><TargetEntity id="756.52" type="ICD9"/><TargetEntity id="10031280" type="MEDDRA"/><TargetEntity id="D010022" type="MeSH"/><TargetEntity id="2781" type="ORPHANET"/><TargetEntity id="-1115994294" type="omicsDisease"/><TargetEntity id="964" type="siCondition"/></SourceEntity><SourceEntity id="1754" type="ciIndication"><TargetEntity id="D016410" type="MeSH"/><TargetEntity id="836" type="siCondition"/></SourceEntity><SourceEntity id="1766" type="ciIndication"><TargetEntity id="10067946" type="MEDDRA"/><TargetEntity id="D002292" type="MeSH"/><TargetEntity id="-994324469" type="omicsDisease"/><TargetEntity id="609" type="siCondition"/></SourceEntity><SourceEntity id="1813" type="ciIndication"><TargetEntity id="B45.1" type="ICD10"/><TargetEntity id="D016919" type="MeSH"/><TargetEntity id="-648854697" type="omicsDisease"/><TargetEntity id="894" type="siCondition"/></SourceEntity><SourceEntity id="197" type="ciIndication"><TargetEntity id="D016773" type="MeSH"/></SourceEntity><SourceEntity id="201" type="ciIndication"><TargetEntity id="10024670" type="MEDDRA"/><TargetEntity id="D008107" type="MeSH"/><TargetEntity id="-35813413" type="omicsDisease"/><TargetEntity id="415" type="siCondition"/></SourceEntity><SourceEntity id="218" type="ciIndication"><TargetEntity id="10062207" type="MEDDRA"/><TargetEntity id="D009164" type="MeSH"/><TargetEntity id="-1047799479" type="omicsDisease"/><TargetEntity id="840" type="siCondition"/></SourceEntity><SourceEntity id="221" type="ciIndication"><TargetEntity id="A15" type="ICD10"/><TargetEntity id="10044755" type="MEDDRA"/><TargetEntity id="D014376" type="MeSH"/><TargetEntity id="3389" type="ORPHANET"/><TargetEntity id="-1043612885" type="omicsDisease"/><TargetEntity id="843" type="siCondition"/></SourceEntity><SourceEntity id="2974" type="ciIndication"><TargetEntity id="10017374" type="MEDDRA"/><TargetEntity id="D005621" type="MeSH"/><TargetEntity id="95" type="ORPHANET"/><TargetEntity id="-1147034178" type="omicsDisease"/><TargetEntity id="86" type="siCondition"/></SourceEntity><SourceEntity id="3074" type="ciIndication"><TargetEntity id="10008906" type="MEDDRA"/><TargetEntity id="D006105" type="MeSH"/><TargetEntity id="379" type="ORPHANET"/><TargetEntity id="-1005310702" type="omicsDisease"/><TargetEntity id="3020" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"/><TargetEntity id="D008228" type="MeSH"/><TargetEntity id="547" type="ORPHANET"/><TargetEntity id="-1008757452" type="omicsDisease"/><TargetEntity id="703" type="siCondition"/></SourceEntity><SourceEntity id="3466" type="ciIndication"><TargetEntity id="4580" type="siCondition"/></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"/><TargetEntity id="589" type="siCondition"/></SourceEntity><SourceEntity id="3771" type="ciIndication"><TargetEntity id="J84.112" type="ICD10"/><TargetEntity id="10021240" type="MEDDRA"/><TargetEntity id="D054990" type="MeSH"/><TargetEntity id="2032" type="ORPHANET"/><TargetEntity id="-1110748304" type="omicsDisease"/><TargetEntity id="289" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"/><TargetEntity id="10033128" type="MEDDRA"/><TargetEntity id="D010051" type="MeSH"/><TargetEntity id="-1370909262" type="omicsDisease"/><TargetEntity id="626" type="siCondition"/></SourceEntity><SourceEntity id="88" type="ciIndication"><TargetEntity id="E84" type="ICD10"/><TargetEntity id="10011762" type="MEDDRA"/><TargetEntity id="D003550" type="MeSH"/><TargetEntity id="586" type="ORPHANET"/><TargetEntity id="-1447400656" type="omicsDisease"/><TargetEntity id="288" type="siCondition"/></SourceEntity><SourceEntity id="95" type="ciIndication"><TargetEntity id="10040831" type="MEDDRA"/><TargetEntity id="D012871" type="MeSH"/><TargetEntity id="-57728907" type="omicsDisease"/><TargetEntity id="442" type="siCondition"/></SourceEntity><SourceEntity id="999" type="ciIndication"><TargetEntity id="C64" type="ICD10"/><TargetEntity id="10038389" type="MEDDRA"/><TargetEntity id="D007680" type="MeSH"/><TargetEntity id="-1866040075" type="omicsDisease"/><TargetEntity id="607" type="siCondition"/></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity></SourceEntity><SourceEntity id="377" type="Action"><TargetEntity id="5382" type="Mechanism">Transforming Growth Factor beta (TGFbeta) Superfamily Proteins Inhibitors</TargetEntity><TargetEntity id="2515" type="Mechanism">Transforming Growth Factor (TGF)-beta Receptor Inhibitors</TargetEntity><TargetEntity id="2805" type="Mechanism">TGF-beta Inhibitors</TargetEntity></SourceEntity><SourceEntity id="225" type="Action"><TargetEntity id="3324" type="Mechanism">Anti-IL4R</TargetEntity><TargetEntity id="659" type="Mechanism">IL-4 Receptor Antagonists</TargetEntity><TargetEntity id="2480" type="Mechanism">IL-4 Antagonists</TargetEntity></SourceEntity><SourceEntity id="1748" type="Action"><TargetEntity id="1059" type="Mechanism">Efflux Pump (Fungal) Inhibitors</TargetEntity><TargetEntity id="1508" type="Mechanism">Homoserine Dehydrogenase (Fungal) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2638" type="Action"><TargetEntity id="4622" type="Mechanism">Drugs Targeting Plasmodium falciparum Proteins</TargetEntity><TargetEntity id="4959" type="Mechanism">Drugs Targeting Parasite Proteins</TargetEntity></SourceEntity><SourceEntity id="PTGT-00985" type="ciTarget"><TargetEntity id="55611" type="siTarget">IL-4 receptor</TargetEntity></SourceEntity><SourceEntity id="PTGT-09261" type="ciTarget"><TargetEntity id="75011253734583" type="siTarget">Interferon gamma</TargetEntity><TargetEntity id="179917650642833" type="siTarget">C-X-C motif chemokine 9</TargetEntity><TargetEntity id="376" type="omicsTarget"/><TargetEntity id="-7784387" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Chronic granulomatous disease - US - Apr-1991</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1265">Osteopetrosis</Indication><Indication id="1754">Cutaneous T-cell lymphoma</Indication><Indication id="1766">Renal cell carcinoma</Indication><Indication id="3074">Chronic granulomatous disease</Indication><Indication id="3466">Metastatic bladder cancer</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1102">Atopic dermatitis</Indication><Indication id="124">Fungal infection</Indication><Indication id="1813">Cryptococcus neoformans meningitis</Indication><Indication id="197">Leishmania tropica infection</Indication><Indication id="201">Liver disease</Indication><Indication id="218">Mycobacterium infection</Indication><Indication id="221">Mycobacterium tuberculosis infection</Indication><Indication id="2974">Friedreich ataxia</Indication><Indication id="31">Asthma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><Indication id="799">Ovary tumor</Indication><Indication id="88">Cystic fibrosis</Indication><Indication id="95">Dermatological disease</Indication><Indication id="999">Renal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="51201">Interferon gamma ligand</Action><Action id="377">TGF beta receptor antagonist</Action><Action id="225">IL-4 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1594">Antibacterial</Action><Action id="1532">Viral replication inhibitor</Action><Action id="15180">Topical antipruritic product</Action><Action id="1748">Fungicide</Action><Action id="2638">Antiparasitic</Action><Action id="2953">Anti-inflammatory</Action><Action id="439">RNA synthesis inhibitor</Action><Action id="858">Collagen synthesis modulator</Action><Action id="664">Fibrosuppressant</Action><Action id="62253">Anticancer hormone</Action><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra><Ephmra><Code>P</Code><Name>PARASITOLOGY</Name></Ephmra><Ephmra><Code>D</Code><Name>DERMATOLOGICALS</Name></Ephmra><Ephmra><Code>J2</Code><Name>SYSTEMIC AGENTS FOR FUNGAL INFECTIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-03-16T07:10:16.000Z</LastModificationDate><ChangeDateLast>2018-08-22T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="19453" linkType="Company"&gt;Genentech&lt;/ulink&gt; and &lt;ulink linkID="14881" linkType="Company"&gt;Boehringer Ingelheim&lt;/ulink&gt;, and  now marketed by &lt;ulink linkID="1053335" linkType="Company"&gt;Horizon Pharma&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="1067362" linkType="Company"&gt;Vidara Therapeutics&lt;/ulink&gt;, which itself had acquired rights from &lt;ulink linkID="26430" linkType="Company"&gt;InterMune&lt;/ulink&gt;, a spin-off from &lt;ulink linkID="15530" linkType="Company"&gt;Connetics&lt;/ulink&gt; (itself a spin-off from Genentech) and  &lt;ulink linkID="1062207" linkType="Company"&gt;Clinigen Group&lt;/ulink&gt; (acquired from Horizon), Actimmune (Imukin; Imukine; Immukin; Immukine) is a bioengineered form of interferon gamma-1b for sc administration [&lt;ulink linkID="2057135" linkType="Reference"&gt;2057135&lt;/ulink&gt;]. The product is indicated for reducing the frequency and severity of serious infections associated with chronic granulomatous disease (CGD) and for delaying time to disease progression in patients with severe, malignant osteopetrosis [&lt;ulink linkID="1998479" linkType="Reference"&gt;1998479&lt;/ulink&gt;], [&lt;ulink linkID="1998484" linkType="Reference"&gt;1998484&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 1991, Genentech had launched the drug in the US for CGD as Actimmune [&lt;ulink linkID="1997837" linkType="Reference"&gt;1997837&lt;/ulink&gt;]. In December 1992, Boehringer Ingelheim launched the product in the UK as Immukin for CGD [&lt;ulink linkID="1998485" linkType="Reference"&gt;1998485&lt;/ulink&gt;]; also in 1992, approval was granted in other European markets for CGD as Imukin  and Boehringer Ingelheim presumably launched the drug elsewhere in Europe that year [&lt;ulink linkID="1997860" linkType="Reference"&gt;1997860&lt;/ulink&gt;], [&lt;ulink linkID="1429015" linkType="Reference"&gt;1429015&lt;/ulink&gt;], [&lt;ulink linkID="1420999" linkType="Reference"&gt;1420999&lt;/ulink&gt;], [&lt;ulink linkID="178550" linkType="Reference"&gt;178550&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By October 2000, Actimmune had been launched in the US for severe, malignant osteopetrosis  [&lt;ulink linkID="387351" linkType="Reference"&gt;387351&lt;/ulink&gt;]. European approval for the treatment of severe, malignant osteopetrosis was granted in 1Q04 [&lt;ulink linkID="580130" linkType="Reference"&gt;580130&lt;/ulink&gt;], [&lt;ulink linkID="598143" linkType="Reference"&gt;598143&lt;/ulink&gt;]. In January 2016, Horizon began a US phase IIa trial in autosomal dominant type 2 osteoporosis [&lt;ulink linkID="1938828" linkType="Reference"&gt;1938828&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Horizon is also developing the drug in oncology settings. In December 2015, Horizon initiated a phase I trial for solid tumors  [&lt;ulink linkID="1721034" linkType="Reference"&gt;1721034&lt;/ulink&gt;]. By May 2016, a phase I combination trial of Actimmune with PD-1/PD-L1 inhibitors was ongoing in patients with advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma (RCC) [&lt;ulink linkID="1870701" linkType="Reference"&gt;1870701&lt;/ulink&gt;]. In April 2017, a phase I/II trial began to assess the product in combination with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt;, &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; and &lt;ulink linkID="28532" linkType="Drug"&gt;pertuzumab&lt;/ulink&gt; in patients with HER2-positive, advanced breast cancer [&lt;ulink linkID="1958597" linkType="Reference"&gt;1958597&lt;/ulink&gt;], [&lt;ulink linkID="1951905" linkType="Reference"&gt;1951905&lt;/ulink&gt;]. In August 2017, Horizon expected to start an investigator-initiated, phase II trial to assess the product in combination with &lt;ulink linkID="70667" linkType="Drug"&gt;pembrolizumab&lt;/ulink&gt; in cutaneous T-cell lymphoma later that year [&lt;ulink linkID="1951905" linkType="Reference"&gt;1951905&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development was previously undertaken in other indications. In September 1996, Connective Therapeutics (then Connetics) initiated a phase III trial in atopic dermatitis [&lt;ulink linkID="220066" linkType="Reference"&gt;220066&lt;/ulink&gt;], [&lt;ulink linkID="1997934" linkType="Reference"&gt;1997934&lt;/ulink&gt;]; in August 1997, Connetics suspended plans to submit a BLA for this indication since the compound failed to show an acceptable therapeutic response with respect to the endpoint [&lt;ulink linkID="260711" linkType="Reference"&gt;260711&lt;/ulink&gt;], [&lt;ulink linkID="261707" linkType="Reference"&gt;261707&lt;/ulink&gt;].  In 1993, Genentech initiated phase III monotherapy trials for RCC [&lt;ulink linkID="1997841" linkType="Reference"&gt;1997841&lt;/ulink&gt;]; however, in July 1996, the trial was discontinued following no clinical benefit over placebo [&lt;ulink linkID="215707" linkType="Reference"&gt;215707&lt;/ulink&gt;]. In August 2000, InterMune began a phase III trial for multidrug resistant tuberculosis (MDR-TB) [&lt;ulink linkID="377540" linkType="Reference"&gt;377540&lt;/ulink&gt;]; development for mycobacterial infections was ongoing in September 2002 [&lt;ulink linkID="477730" linkType="Reference"&gt;477730&lt;/ulink&gt;]; however, no development has been reported since then. In October 2000, InterMune initiated a phase III trial idiopathic pulmonary fibrosis  (IPF)  [&lt;ulink linkID="387351" linkType="Reference"&gt;387351&lt;/ulink&gt;]; in December 2003, InterMune began the pivotal phase III INSPIRE study in IPF [&lt;ulink linkID="517268" linkType="Reference"&gt;517268&lt;/ulink&gt;]; in March 2007, the trial was terminated  [&lt;ulink linkID="770946" linkType="Reference"&gt;770946&lt;/ulink&gt;]; however, in December 2011, licensee mondoBIOTECH (then THERAMetrics; now &lt;ulink linkID="29586" linkType="Company"&gt;Relief Therapeutics Holding&lt;/ulink&gt;)'s pipeline listed the drug in phase II for IPF [&lt;ulink linkID="1250837" linkType="Reference"&gt;1250837&lt;/ulink&gt;],  [&lt;ulink linkID="1457127" linkType="Reference"&gt;1457127&lt;/ulink&gt;], [&lt;ulink linkID="1780697" linkType="Reference"&gt;1780697&lt;/ulink&gt;]; while in January 2012,  mondoBIOTECH listed the drug   as being in phase I development for IPF [&lt;ulink linkID="1261324" linkType="Reference"&gt;1261324&lt;/ulink&gt;], [&lt;ulink linkID="1260550" linkType="Reference"&gt;1260550&lt;/ulink&gt;]; however, no further development has been reported since that time. In February 2002, a phase III trial for ovarian cancer began [&lt;ulink linkID="438505" linkType="Reference"&gt;438505&lt;/ulink&gt;]; in January 2006, InterMune expected to file an ovarian cancer BLA in mid-2008 and to launch the drug in 2010 [&lt;ulink linkID="645289" linkType="Reference"&gt;645289&lt;/ulink&gt;]; however, development for this indication was terminated in February 2006 over safety concerns [&lt;ulink linkID="648407" linkType="Reference"&gt;648407&lt;/ulink&gt;]. By March 2003, InterMune initiated a phase III trial in cryptococcal meningitis [&lt;ulink linkID="487490" linkType="Reference"&gt;487490&lt;/ulink&gt;]; however, no development has been reported since then.  In June 2015, Horizon initiated a phase III trial (STEADFAST) for Friedreich ataxia [&lt;ulink linkID="1667146" linkType="Reference"&gt;1667146&lt;/ulink&gt;], [&lt;ulink linkID="1667331" linkType="Reference"&gt;1667331&lt;/ulink&gt;]; however, in December 2016, negative topline data from the STEADFAST trial were reported and a decision was made to  discontinue the entire Friedreich ataxia clinical program [&lt;ulink linkID="1883711" linkType="Reference"&gt;1883711&lt;/ulink&gt;]. In February 2001, InterMune initiated a phase II trial of inhaled Actimmune in the treatment of cystic fibrosis (CF) [&lt;ulink linkID="400450" linkType="Reference"&gt;400450&lt;/ulink&gt;]; however, no development has been reported since then. In January 2002, a phase II trial began for liver fibrosis [&lt;ulink linkID="435167" linkType="Reference"&gt;435167&lt;/ulink&gt;];  in January 2004, Actimmune failed to meet its primary endpoint of reversal of liver fibrosis in a phase II trial in patients with advanced liver fibrosis caused by HCV that had failed standard antiviral therapy [&lt;ulink linkID="519793" linkType="Reference"&gt;519793&lt;/ulink&gt;]. In April 2002, InterMune and mondoBIOTECH began a phase II study for asthma [&lt;ulink linkID="447143" linkType="Reference"&gt;447143&lt;/ulink&gt;]; however, no development has been reported since then. By March 2003,  phase II trials for invasive aspergillosis and non-Hodgkin's lymphoma (NHL) were ongoing [&lt;ulink linkID="487490" linkType="Reference"&gt;487490&lt;/ulink&gt;]; however, in March 2004, development for NHL was discontinued for strategic reasons and no further development for  invasive aspergillosis was reported [&lt;ulink linkID="1137480" linkType="Reference"&gt;1137480&lt;/ulink&gt;]. Other potential indications, such as infection in patients suffering from immunosuppression and dysfunction of the immune system,  visceral leishmaniasis, were being studied by InterMune or Boehringer Ingelheim [&lt;ulink linkID="178550" linkType="Reference"&gt;178550&lt;/ulink&gt;], [&lt;ulink linkID="178570" linkType="Reference"&gt;178570&lt;/ulink&gt;]; however, no further development has been reported.&lt;/para&gt;&lt;para&gt;InterMune and Maxygen were also investigating a once-weekly version of the product for IPF and other indications [&lt;ulink linkID="466030" linkType="Reference"&gt;466030&lt;/ulink&gt;], [&lt;ulink linkID="670326" linkType="Reference"&gt;670326&lt;/ulink&gt;]. By October 2002, Ithe next-generation version of gamma interferon that could be taken once weekly rather than three times a week was in preclinical development [&lt;ulink linkID="466030" linkType="Reference"&gt;466030&lt;/ulink&gt;]; in March 2006, this was still the case [&lt;ulink linkID="670326" linkType="Reference"&gt;670326&lt;/ulink&gt;]; however, no further development has been reported.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In May 2002, InterMune acquired the interferon gamma-1b patent estate of &lt;ulink linkID="14109" linkType="Company"&gt;Amgen&lt;/ulink&gt; that was in question with the interferon-g-1b patents of Genentech, thereby ending issues between Genentech and Amgen concerning their respective patent claims in North America and Europe [&lt;ulink linkID="451036" linkType="Reference"&gt;451036&lt;/ulink&gt;]. In March 2005, InterMune stated that certain US patents covering DNA vectors and host cells relating to interferon gamma-1b expiring in 2005 (US-04727138, US-04762791 and &lt;ulink linkID="IN1480630" linkType="Patent"&gt;US-04929554&lt;/ulink&gt;) and 2006 (&lt;ulink linkID="IN1474795" linkType="Patent"&gt;US-04855238&lt;/ulink&gt;) without material impact to the company's business. In addition, a US patent relating to the composition of interferon gamma-1b expires in 2014 (&lt;ulink linkID="IN2686443" linkType="Patent"&gt;US-05690925&lt;/ulink&gt;); other material US patents expire in 2009 (&lt;ulink linkID="IN1493440" linkType="Patent"&gt;US-05096705&lt;/ulink&gt;) and 2013 (&lt;ulink linkID="IN2685005" linkType="Patent"&gt;&lt;/ulink&gt;US-05582824 and US-05574137) [&lt;ulink linkID="591562" linkType="Reference"&gt;591562&lt;/ulink&gt;], [&lt;ulink linkID="678534" linkType="Reference"&gt;678534&lt;/ulink&gt;]. In October 2005, the company announced that two new US composition patents have been issued which extend the company's intellectual property rights to the drug to 2022 [&lt;ulink linkID="630980" linkType="Reference"&gt;630980&lt;/ulink&gt;]. In February 2017, Horizon noted that patent protection expires in 2022 [&lt;ulink linkID="1903963" linkType="Reference"&gt;1903963&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Chronic granulomatous disease&lt;/subtitle&gt;In September 1988, the drug received  Orphan Drug designation by the FDA for the treatment of CGD [&lt;ulink linkID="1997827" linkType="Reference"&gt;1997827&lt;/ulink&gt;]. In December 1989, Genetech filed a Product License Application (PLA) for US approval for CGD [&lt;ulink linkID="1997827" linkType="Reference"&gt;1997827&lt;/ulink&gt;]. In December 1990, the drug was approved [&lt;ulink linkID="1997830" linkType="Reference"&gt;1997830&lt;/ulink&gt;]. By April 1991, launch had occurred [&lt;ulink linkID="1997837" linkType="Reference"&gt;1997837&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Osteopetrosis&lt;/subtitle&gt;In August 1999, InterMune submitted a BLA in the US for  osteopetrosis  based on positive phase III data [&lt;ulink linkID="337568" linkType="Reference"&gt;337568&lt;/ulink&gt;]. In February 1999, the drug was approved in the US [&lt;ulink linkID="1484863" linkType="Reference"&gt;1484863&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Idiopathic pulmonary fibrosis&lt;/subtitle&gt;In January 2002, the FDA designated Actimmune as a Fast Track drug for the treatment of idiopathic pulmonary fibrosis (IPF) [&lt;ulink linkID="434993" linkType="Reference"&gt;434993&lt;/ulink&gt;] and in September 2002, Actimmune was granted Orphan Drug status in the US [&lt;ulink linkID="507427" linkType="Reference"&gt;507427&lt;/ulink&gt;]. In August 2012, the Orphan Drug status for IPF in the US was transferred to mondoBIOTECH [&lt;ulink linkID="1316446" linkType="Reference"&gt;1316446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Friedreich ataxia&lt;/subtitle&gt;In October 2014, the US FDA granted Orphan Drug status for the treatment of Friedreich ataxia [&lt;ulink linkID="1599736" linkType="Reference"&gt;1599736&lt;/ulink&gt;]. In February 2015, the company requested for the Fast Track Designation for the treatment of Friedreich ataxia [&lt;ulink linkID="1633772" linkType="Reference"&gt;1633772&lt;/ulink&gt;]. In April 2015, the FDA granted Fast Track designation for the treatment of Friedreich ataxia [&lt;ulink linkID="1649719" linkType="Reference"&gt;1649719&lt;/ulink&gt;]. In May 2016, sBLA submission was expected in the first-quarter of  2017 [&lt;ulink linkID="1760375" linkType="Reference"&gt;1760375&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;&lt;subtitle&gt;Chronic granulomatous disease&lt;/subtitle&gt;In December 1992, Boehringer Ingelheim launched the product in the UK as Immukin for CGD [&lt;ulink linkID="1998485" linkType="Reference"&gt;1998485&lt;/ulink&gt;]; also in 1992, approval was granted in other European markets for CGD as Imukin  and Boehringer Ingelheim presumably launched the drug elsewhere in Europe later that year [&lt;ulink linkID="1997860" linkType="Reference"&gt;1997860&lt;/ulink&gt;], [&lt;ulink linkID="1429015" linkType="Reference"&gt;1429015&lt;/ulink&gt;], [&lt;ulink linkID="1420999" linkType="Reference"&gt;1420999&lt;/ulink&gt;], [&lt;ulink linkID="178550" linkType="Reference"&gt;178550&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Osteopetrosis&lt;/subtitle&gt;European approval for the treatment of severe, malignant osteopetrosis was granted in 1Q04 [&lt;ulink linkID="580130" linkType="Reference"&gt;580130&lt;/ulink&gt;],, [&lt;ulink linkID="598143" linkType="Reference"&gt;598143&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Idiopathic pulmonary fibrosis&lt;/subtitle&gt;By February 2012, mondoBIOTECH had been  granted Orphan Drug status in Europe for IPF [&lt;ulink linkID="1260550" linkType="Reference"&gt;1260550&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In January 2001, InterMune filed an NDS with the Therapeutics Products Programme of Health Canada (TPP) to market Actimmune in Canada for the treatment of severe malignant osteopetrosis (as well as chronic granulomatous disease). The TPP granted the NDS priority status and InterMune expected approval within 6 months [&lt;ulink linkID="394975" linkType="Reference"&gt;394975&lt;/ulink&gt;], [&lt;ulink linkID="399218" linkType="Reference"&gt;399218&lt;/ulink&gt;]. In May 2006, InterMune confirmed that the drug was available in Canada through the Special Access Program (SAP) for patients with serious or life-threatening conditions [&lt;ulink linkID="673272" linkType="Reference"&gt;673272&lt;/ulink&gt;]. In May 2016, the product was not approved in Canada; at that time,  Actimmune was still available through the SAP [&lt;ulink linkID="2065850" linkType="Reference"&gt;2065850&lt;/ulink&gt;];  no further regulatory development in Canada has been reported for some time.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In December 1999, the drug was granted Orphan Drug  designation in Taiwan for CGD [&lt;ulink linkID="1685979" linkType="Reference"&gt;1685979&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Idiopathic pulmonary fibrosis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In December 2003, InterMune began enrollment into the pivotal phase III INSPIRE study [&lt;ulink linkID="517268" linkType="Reference"&gt;517268&lt;/ulink&gt;]. In April 2005, the company expected to complete patient enrollment by the end of that year [&lt;ulink linkID="598382" linkType="Reference"&gt;598382&lt;/ulink&gt;]. However, an interim analysis showed the overall mortality rate was lower than the projections used in designing the trial. To improve the likelihood of reaching the number of events required to reach statistical significance by the end of 2007 when the trial was scheduled to finish, InterMune decided to recruit a further 200 patients [&lt;ulink linkID="628921" linkType="Reference"&gt;628921&lt;/ulink&gt;]. In November 2005, 600 patients were enrolled [&lt;ulink linkID="633624" linkType="Reference"&gt;633624&lt;/ulink&gt;], [&lt;ulink linkID="637607" linkType="Reference"&gt;637607&lt;/ulink&gt;]. InterMune completed enrollment in April 2006; the study recruited 826 IPF patients with mild-to-moderate lung function impairment. The trial was monitoring survival time in patients receiving 200 microg of Actimmune subcutaneously three times a week. At that time, the company expected to complete the trial in late-2007 and to report top-line data in early-2008 [&lt;ulink linkID="662154" linkType="Reference"&gt;662154&lt;/ulink&gt;]. However, the INSPIRE trial was terminated in March 2007, following an interim analysis which found no effect on survival. Overall mortality  was 14.5% in the  treated group as compared to 12.7% in the placebo group [&lt;ulink linkID="770946" linkType="Reference"&gt;770946&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2005, multiple studies of Actimmune were presented at the annual International Conference of the American Thoracic Society in San Diego, CA. The outcome of long-term use of the drug was analysed using efficacy and safety data from 70 patients who completed the phase III GIPF-001 and GIPF-004 trials. Relatively stable lung function was seen after treatment for an average of 2.5 years. Serious adverse events (SAE) occurred in 29 patients, of which 10 were possibly related to Actimmune. Of the respiratory SAEs seen in 20 patients, 7 were possibly related to Actimmune. Additionally, a meta-analysis of the drug studied pooled data from three long-term, randomized controlled trials that included 390 patients. The drug was associated with prolonged survival at 1 year, 18 months, 650 days and 2 years. Preclinical data was also presented [&lt;ulink linkID="603283" linkType="Reference"&gt;603283&lt;/ulink&gt;]. Further GIPF-001 data was presented in January 2006 at JP Morgan's 24th Annual Healthcare Conference in San Francisco, CA, showing Actimmune cut mortality by 41% in 330 patients. The cut in mortality was higher in less-serious cases [&lt;ulink linkID="645289" linkType="Reference"&gt;645289&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2004, data from a 48-week, open-label study (GIPF-004) was presented at the 70th Annual Meeting of the American College of Chest Physicians (ACCP) in Seattle, WA, which showed the initiation of treatment with Actimmune for IPF treatment was safe and not associated with an excess of SAEs, compared with patients receiving long-term treatment. The rates and characteristics of SAEs in the safety study were compared in two groups of patients: 101 patients originally assigned to receive placebo in the phase III trial (newly treated patients) and 109 patients who received treatment with Actimmune in the phase III trial (long-term patients). SAEs occurred in 40% of newly treated patients and in 36% of long-term patients, respectively, suggesting that there was no increase in risk of acute respiratory decompensation associated with starting Actimmune treatment [&lt;ulink linkID="567502" linkType="Reference"&gt;567502&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2003, follow-up data from a phase III IPF trial was presented at the 99th International Conference of the American Thoracic Society in Seattle, WA. While no significant effect was observed on the primary endpoint, conventional measures of physiological function or quality-of-life scales, a prespecified analysis of survival suggested that Actimmune conferred a survival benefit to IPF patients in the intent-to-treat population. The survival benefit was more pronounced in the prespecified cohort of treatment adherent patients, defined as patients receiving greater than 80% of scheduled doses and in patients who had less severely impaired lung function at baseline. An exploratory analysis also suggested a trend toward less dyspnea after 48 weeks. Separately, results from an interim analysis of an independent randomized controlled trial were presented, in which a significant survival benefit was observed in Actimmune-treated IPF patients [&lt;ulink linkID="490206" linkType="Reference"&gt;490206&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2003, Intermune presented preliminary survival data from the follow-up observation period of the completed phase III, at the JPMorgan H&amp;amp;Q 21st Healthcare meeting in San Francisco, CA. Patients were followed for 3 to 5 additional months beyond the pre-specified analysis of the phase III trial. There were 16% deaths in the Actimmune treated group, compared with 21.4% in the placebo group [&lt;ulink linkID="475942" linkType="Reference"&gt;475942&lt;/ulink&gt;]. Final results of the pre-specified analysis from the phase III trial showed that Actimmune did not demonstrate significant efficacy with respect to the primary or secondary endpoints. However, the overall analysis of survival, a secondary endpoint in the trial, suggested that Actimmune may provide a survival benefit for patients with mild-to-moderate impairment in lung function [&lt;ulink linkID="477998" linkType="Reference"&gt;477998&lt;/ulink&gt;]. In March 2003, data from this trial was presented at the Cytokines and Beyond GTCBIO conference, San Diego, CA, showing that Actimmune treatment significantly impacted survival in treated patients, particularly in those patients with a FVC over 55% [&lt;ulink linkID="487790" linkType="Reference"&gt;487790&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2000, InterMune initiated a phase III trial (GIPF-001) to evaluate the safety and efficacy of Actimmune for IPF treatment [&lt;ulink linkID="384646" linkType="Reference"&gt;384646&lt;/ulink&gt;], [&lt;ulink linkID="399218" linkType="Reference"&gt;399218&lt;/ulink&gt;], [&lt;ulink linkID="407146" linkType="Reference"&gt;407146&lt;/ulink&gt;]. By July 2001, 300 patients had been signed up to the US and European trials of Actimmune [&lt;ulink linkID="417026" linkType="Reference"&gt;417026&lt;/ulink&gt;]. Enrollment was completed in August 2001, with results expected by November 2002 [&lt;ulink linkID="419937" linkType="Reference"&gt;419937&lt;/ulink&gt;], [&lt;ulink linkID="430700" linkType="Reference"&gt;430700&lt;/ulink&gt;]. In August 2002, InterMune released preliminary data from a double-blind, placebo-controlled phase III trial. A total of 330 patients received either placebo or 200 microg Actimmune sc 3 times weekly. All patients remained in the trial to 48 weeks and median treatment duration was 60 weeks. The primary endpoint was progression free survival time defined as: a decrease in forced vital capacity (FVC) of &amp;gt;10 %; an increase in A-a gradient of 5 mmHg; or, death. The endpoint did not reach significance but there was a trend in favor of treated patients, representing an approximately 10% relative reduction in the rate of progression-free survival versus placebo. The drug also demonstrated a positive trend in increased survival in the overall patient population and a significant survival benefit in patients with mild-to-moderate IPF. In the overall population, there was a 9.9% death rate in the treated group, compared with 16.7% in the placebo group, representing a 40% decrease in mortality in favor of Actimmune versus placebo (p = 0.084). Of the 254 patients with mild-to-moderate disease, there was a 4.8% death rate in the treated group and 16.4% in the placebo group, representing a 70% decrease in mortality in favor of Actimmune versus placebo (p = 0.004). There were also trends later in the study towards improved breathing and reduced need for supplemental oxygen. Actimmune treatment was well tolerated, with the most common side effects being influenza-like symptoms. At this time, InterMune planned to transition all remaining phase III trial patients in the active and placebo groups into an open-label study to track longer-term outcomes with Actimmune for a minimum of 1 year [&lt;ulink linkID="462658" linkType="Reference"&gt;462658&lt;/ulink&gt;], [&lt;ulink linkID="464383" linkType="Reference"&gt;464383&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 1999, results of a randomized, controlled clinical study of Actimmune for the treatment of IPF, conducted by InterMune in Austria, demonstrated that those treated with Actimmune plus an oral glucocorticoid showed significant improvements in lung condition, compared with those who received glucocorticoid alone, who experienced a deterioration in lung function. Actimmune was well tolerated with mild side effects, which included fever, chills and muscle pain [&lt;ulink linkID="346608" linkType="Reference"&gt;346608&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2004, InterMune published data from an exploratory phase II trial investigating the effects of Actimmune on the expression of biological markers associated with IPF. The randomized, double blind, placebo-controlled trial enrolled 32 IPF patients at 15 medical centers across the US. Patients received 200 microg of Actimmune subcutaneously three times weekly, or placebo, for 6 months. The primary endpoints were changes in mRNA gene expression of transforming growth factor-beta (TGF-beta) and connective tissue growth factor (CTGF). Other endpoints included changes in mRNA and protein biomarkers for profibrotic molecules, cytokines, chemokines, antimicrobial peptides and additional growth factors, clinical measures of lung function and patient safety. No significant difference was observed for the changes in mRNA transcription levels for TGF-beta and CTGF. Synthesis of I-TAC/CXCL11, a CXC chemokine with known immunomodulatory, antimicrobial, and anti-angiogenic properties, was markedly increased. Actimmune appeared to influence a number of biomarkers that may be relevant in the pathogenesis of IPF. No significant changes were observed in clinical measures of lung function. Actimmune was generally well tolerated and side effects were consistent with influenza-like symptoms [&lt;ulink linkID="529789" linkType="Reference"&gt;529789&lt;/ulink&gt;], [&lt;ulink linkID="529532" linkType="Reference"&gt;529532&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2000, InterMune announced the release of independent corroboration of its phase II trial results (in a monograph published by the American Thoracic Society), confirming that lung function improved in patients treated with Actimmune plus prednisolone and worsened in patients treated with prednisolone alone [&lt;ulink linkID="384289" linkType="Reference"&gt;384289&lt;/ulink&gt;]. In May 2002, InterMune reported long-term follow-up data from a phase II trial of Actimmune in IPF patients.  The data demonstrated a mortality benefit in IPF patients randomly assigned to Actimmune versus control treatment [&lt;ulink linkID="452123" linkType="Reference"&gt;452123&lt;/ulink&gt;]. In March 2003, at the Cytokines and Beyond Conference, San Diego, CA, results from a small phase II study, were presented showing that Actimmune produced a 78% relative reduction in mortality in IPF patients, compared with the control group [&lt;ulink linkID="487790" linkType="Reference"&gt;487790&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2000, InterMune responded to a published letter, which claimed that results from the phase II Austrian study of Actimmune for the potential treatment of IPF were questionable. The allegations, centered around the exact diagnosis of some of the patients in the study, were originally published in October 1999. Since October 1999, InterMune has completed several independent reviews of the study and is confident that these patients were diagnosed correctly with IPF [&lt;ulink linkID="361024" linkType="Reference"&gt;361024&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In February 2002, InterMune commenced enrolling patients in a phase III US trial (GRACES) of Actimmune as an adjunctive first-line treatment for ovarian cancer. This multicenter, randomized trial was designed to evaluate the efficacy and safety of the agent in combination with &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; plus &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; in 800 patients diagnosed with advanced ovarian cancer [&lt;ulink linkID="438505" linkType="Reference"&gt;438505&lt;/ulink&gt;], [&lt;ulink linkID="425882" linkType="Reference"&gt;425882&lt;/ulink&gt;], [&lt;ulink linkID="430700" linkType="Reference"&gt;430700&lt;/ulink&gt;]. In April 2004, InterMune completed enrollment [&lt;ulink linkID="533134" linkType="Reference"&gt;533134&lt;/ulink&gt;]. In November 2005, InterMune expected to report interim data in the first quarter of 2006 [&lt;ulink linkID="637607" linkType="Reference"&gt;637607&lt;/ulink&gt;] and in January 2006, InterMune expected the trial to reach its overall survival endpoint in 2008 [&lt;ulink linkID="645289" linkType="Reference"&gt;645289&lt;/ulink&gt;]. However, in February 2006, development was discontinued over safety concerns. After calculating progression-free survival (PFS) and overall survival, it was found that 39.7% subjects in the Actimmune group died, compared with 30.4% of patients who received chemotherapy alone; there was no difference in PFS between the groups. Preliminary exploratory analyses suggested the difference in overall survival between the groups might have been related to chemotherapy dose reductions. As of 24% of patients in the Actimmune group did not complete all six cycles of &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt;/&lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt;, compared with 17% of patients in the control group [&lt;ulink linkID="648407" linkType="Reference"&gt;648407&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2000, InterMune planned to initiate a trial to evaluate Actimmune as part of a first-line therapy for invasive ovarian cancer. The decision followed an independent review of the results of a European trial, which itself was then the subject of a review. The study was a randomized controlled trial in 148 women who had undergone primary surgery for ovarian cancer, with the control arm receiving cisplatin and cyclophosphamide, and the experimental arm adding Actimmune to this regimen. Progression-free survival at 3 years was improved from 38% in the control arm to 51% in the treatment group. This corresponded to median times to progression of 17 and 48 months and a 3-year overall survival of 58% and 74%, respectively [&lt;ulink linkID="383530" linkType="Reference"&gt;383530&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1993, Genentech initiated phase III trials for RCC [&lt;ulink linkID="1997841" linkType="Reference"&gt;1997841&lt;/ulink&gt;]. In July 1996, however, the trial was discontinued following no clinical benefit over the placebo [&lt;ulink linkID="215707" linkType="Reference"&gt;215707&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2017, Horizon expected to start an investigator-initiated, &lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt;-supported, phase II trial to assess the product in combination with &lt;ulink linkID="70667" linkType="Drug"&gt;pembrolizumab&lt;/ulink&gt; in cutaneous T-cell lymphoma later that year [&lt;ulink linkID="1951905" linkType="Reference"&gt;1951905&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, an open-label, single-group assignment, phase I/II trial (&lt;ulink linkID="294802" linkType="Protocol"&gt;NCT03112590&lt;/ulink&gt;; MCC-18936) began in the US to assess the product in combination with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt;, &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; and &lt;ulink linkID="28532" linkType="Drug"&gt;pertuzumab&lt;/ulink&gt; in patients (expected n = 43) with HER2-positive, advanced breast cancer. Primary endpoint of the phase I portion was the recommended phase II dose and the phase II portion was pathologic complete response after post therapy surgery at approximately 12 weeks. In May 2017, the trial was expected to complete in June 2021 [&lt;ulink linkID="1958597" linkType="Reference"&gt;1958597&lt;/ulink&gt;], [&lt;ulink linkID="1951905" linkType="Reference"&gt;1951905&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2001, InterMune was planning to evaluate Actimmune, in combination with &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt;, as a potential second-line therapy for the treatment of NHL [&lt;ulink linkID="414182" linkType="Reference"&gt;414182&lt;/ulink&gt;], [&lt;ulink linkID="417026" linkType="Reference"&gt;417026&lt;/ulink&gt;]. By September 2002, the company planned to initiate phase II trials for the potential treatment of relapsed or refractory, low grade or follicular, B-cell NHL [&lt;ulink linkID="477730" linkType="Reference"&gt;477730&lt;/ulink&gt;]. By March 2003,  a phase II trial for NHL was ongoing [&lt;ulink linkID="487490" linkType="Reference"&gt;487490&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2000, results of a phase II trial examining the potential therapeutic utility of Actimmune for metastatic melanoma were presented at the 36th ASCO meeting in New Orleans, LA. Actimmune had clinical efficacy (15% response rate) with very low toxicity [&lt;ulink linkID="368832" linkType="Reference"&gt;368832&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In July 2015, Horizon, in collaboration with investigators Fox Chase Cancer Center, was planning to conduct a study of Actimmune in combination with PD-1/PD-L1 inhibitors in patients with advanced bladder cancer and RCC, following a  dose-ranging study to determine a suitable dose, by the end of  2015 [&lt;ulink linkID="1680636" linkType="Reference"&gt;1680636&lt;/ulink&gt;], [&lt;ulink linkID="1711566" linkType="Reference"&gt;1711566&lt;/ulink&gt;]. In December 2015, Horizon Pharma in collaboration with &lt;ulink linkID="21112" linkType="Company"&gt;Fox Chase Cancer Center&lt;/ulink&gt; initiated an open-label, single-group, phase I trial (&lt;ulink linkID="246922" linkType="Protocol"&gt;NCT02614456&lt;/ulink&gt;; GU-084) in the US to evaluate the safety of Actimmune in combination with &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; for patients (expected n = 15) with advanced solid tumors. The primary endpoint included the number of treatment-related adverse events and to determine the recommended phase II dose. At that time, the trial was expected to complete in December 2018 [&lt;ulink linkID="1721335" linkType="Reference"&gt;1721335&lt;/ulink&gt;], [&lt;ulink linkID="1721034" linkType="Reference"&gt;1721034&lt;/ulink&gt;].  In May 2016, the first six-patient cohort was completed. In September 2016, the second six-patient cohort was completed. In November 2016, patient enrollment for the third cohort was ongoing [&lt;ulink linkID="1870701" linkType="Reference"&gt;1870701&lt;/ulink&gt;]. In February 2017, preliminary data from the first two cohorts were presented at the American Society for Clinical Oncology - Society for Immunotherapy of Cancer meeting in Orlando, FL. Data demonstrated that combination was safe and well-tolerated in the first two cohorts. The data also showed statistically significant activation of certain monocytes, or white blood cells in peripheral blood, which demonstrates that ACTIMMUNE is having the desired effect of stimulating immune cells. At that time, the third cohort of patients was under study [&lt;ulink linkID="1904226" linkType="Reference"&gt;1904226&lt;/ulink&gt;]. In August 2017, the dose-escalation trial was enrolling patients in the fourth cohort and preliminary data in the first three cohorts were reported showing a favorable safety profile of the combination. At that time, dosing level results were expected later that year [&lt;ulink linkID="1951905" linkType="Reference"&gt;1951905&lt;/ulink&gt;]. By February 2018, the trial was expected to complete in December 2021. At that time, recruitment was ongoing [&lt;ulink linkID="1721335" linkType="Reference"&gt;1721335&lt;/ulink&gt;]. In November 2018, further data of 26 patients across four dose cohorts were presented at the 33rd SITC Annual Meeting in Washington DC. A total of three DLTs were reported; two at highest dose level of 100 microg/m2. The MTD was determined to be 75 microg/m2. The recommended phase II dose (primary endpoint) was determined to 50 microg/m2 [&lt;ulink linkID="2093114" linkType="Reference"&gt;2093114&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Chronic granulomatous disease&lt;/subtitle&gt;In December 1990, data from a phase III trial  in 128 patients were reported showing that CGD patients receiving Actimmune with antibiotic therapy had fewer and less severe serious infections and hospitalizations than CGD patients receiving antibiotics alone. The primary endpoint was time to serious infection. The trial was terminated early due to significant efficacy on the primary endpoint (p=0.0036). Compared with placebo, patients receiving Actimmune experienced a 64% reduction in total number and rate of serious infections, 67% fewer inpatient hospital days and a 67% reduction in the relative risk of serious infections [&lt;ulink linkID="1997830" linkType="Reference"&gt;1997830&lt;/ulink&gt;], [&lt;ulink linkID="1641852" linkType="Reference"&gt;1641852&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Mycobacterial infection&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In August 2000, InterMune commenced enrollment for the phase III safety and efficacy trial for multidrug resistant tuberculosis (MDR-TB) in patients who had failed a treatment regimen of antituberculosis therapy [&lt;ulink linkID="377540" linkType="Reference"&gt;377540&lt;/ulink&gt;]. At this time, the company planned to develop Actimmune for the treatment of mycobacterial diseases other than MDR-TB, including newly diagnosed drug-sensitive tuberculosis and atypical mycobacterial infections. A phase II trial for the treatment of atypical mycobacterial infections was slated to begin later in 2000 [&lt;ulink linkID="377540" linkType="Reference"&gt;377540&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In January 2001, InterMune initiated the enrollment of a phase II trial of Actimmune in pulmonary atypical mycobacterial infections [&lt;ulink linkID="394976" linkType="Reference"&gt;394976&lt;/ulink&gt;], [&lt;ulink linkID="399218" linkType="Reference"&gt;399218&lt;/ulink&gt;]. Clinical trials in atypical mycobacterial infections were ongoing in September 2002 [&lt;ulink linkID="477730" linkType="Reference"&gt;477730&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cryptococcal meningitis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;By September 2002, phase III trials for cryptococcal meningitis were anticipated to begin in 2003 [&lt;ulink linkID="477730" linkType="Reference"&gt;477730&lt;/ulink&gt;]. By March 2003, InterMune initiated a phase III trial in cryptococcal meningitis [&lt;ulink linkID="487490" linkType="Reference"&gt;487490&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2000, InterMune initiated a phase II trial evaluating the safety, efficacy and dosing of Actimmune in the treatment of cryptococcal meningitis. The study was to be conducted at seven medical centers in the US and two centers in Peru, and was expected to enroll 60 patients. In June 2001, the phase II trials were ongoing [&lt;ulink linkID="414182" linkType="Reference"&gt;414182&lt;/ulink&gt;], [&lt;ulink linkID="354281" linkType="Reference"&gt;354281&lt;/ulink&gt;]. Enrollment was completed by April 2001, with 79 patients with cryptococcal meningitis having been recruited; at this time, results were expected in the fourth quarter of 2001 [&lt;ulink linkID="404317" linkType="Reference"&gt;404317&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Osteopetrosis&lt;/subtitle&gt;In January 2016, an open-label, single-group, open-label, phase IIa trial (&lt;ulink linkID="243798" linkType="Protocol"&gt;NCT02584608&lt;/ulink&gt;; 1510340687) began in the US to assess the drug in patients (expected n = 12) with autosomal dominant type 2 osteoporosis. The primary endpoint was bone resorption markers at 14 weeks. In July 2016, the trial  was expected to complete in December 2020 [&lt;ulink linkID="1938828" linkType="Reference"&gt;1938828&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2014, a randomized  trial had been initiated to assess Actimmune plus calcitriol versus calcitriol alone in subjects (expected n = 16) with severe malignant osteopetrosis. The trial was completed by December 2014. The median time to progression in patients receiving Actimmune with calcitriol was 165 days, versus  65 days for calcitriol alone [&lt;ulink linkID="1641852" linkType="Reference"&gt;1641852&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;As of April 1999, InterMune had completed a phase III trial of Actimmune for the treatment of congenital osteopetrosis [&lt;ulink linkID="597107" linkType="Reference"&gt;597107&lt;/ulink&gt;]. In the trial, InterMune assessed efficacy by comparing the length of time to progression of disease, defined as either death, serious infection, blood disorder or neurological complication in patients receiving Actimmune versus control. In Actimmune-treated patients there was a significant increase in the time to disease progression (263 days compared to 130 days in the control group) [&lt;ulink linkID="337568" linkType="Reference"&gt;337568&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Atopic dermatitis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 1996, &lt;ulink linkID="15530" linkType="Company"&gt;Connetics&lt;/ulink&gt; (now &lt;ulink linkID="20255" linkType="Company"&gt;Stiefel Laboratories&lt;/ulink&gt;, a subsidiary of &lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; (GSK))  began a phase III trial in atopic dermatitis [&lt;ulink linkID="220066" linkType="Reference"&gt;220066&lt;/ulink&gt;]. The multicenter, randomized, double-blind study expected to enroll approximately 500 patients in 3 parallel groups, consisting of 2 active groups (50 microg/m2 per day and 50 microg/m2 every other day) and placebo. Patients were to receive sc injections over a 12-week treatment period and then a 4-week follow up to assess duration of response. Primary endpoints included assessment of total clinical severity based upon erythema, palpation and excoriation scores. In March 1997, the company reported that phase III trial enrollment was complete [&lt;ulink linkID="235466" linkType="Reference"&gt;235466&lt;/ulink&gt;], [&lt;ulink linkID="239926" linkType="Reference"&gt;239926&lt;/ulink&gt;]. In August 1997, Connetics suspended plans to submit a BLA for this indication since the compound failed to show an acceptable therapeutic response with respect to the endpoint [&lt;ulink linkID="260711" linkType="Reference"&gt;260711&lt;/ulink&gt;], [&lt;ulink linkID="261707" linkType="Reference"&gt;261707&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 1997, clinical results from long-term administration of Actimmune in adults and children with severe atopic dermatitis were presented at the American Academy of Allergy, Asthma and Immunology Meeting in San Francisco, CA. The data was generated in an open label phase II study in 14 patients who previously completed a 12-week, double-blind, placebo-controlled trial. The amount of skin area affected by disease before therapy averaged 62%, while after gamma interferon therapy, the skin involvement was reduced to approximately 19%. Side effects were minimal. The data supported previous clinical safety and efficacy results [&lt;ulink linkID="235466" linkType="Reference"&gt;235466&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results from a phase II trial of Actimmune for the treatment of atopic dermatitis demonstrated significant improvement in clinical scores of erythema and excoriation, and in global assessment of disease improvement. Side effects were minimal and no significant changes in the safety profile were apparent after 2 years of chronic use [&lt;ulink linkID="220066" linkType="Reference"&gt;220066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cystic fibrosis&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2001, InterMune initiated a phase II trial of inhaled Actimmune in the treatment of CF [&lt;ulink linkID="400450" linkType="Reference"&gt;400450&lt;/ulink&gt;]. It was anticipated that 60 CF patients at eight medical centers in the US would participate in the double-blind trial investigating safety and efficacy. According to the protocol, approximately one-third of the patients were to receive placebo and the remaining two-thirds were to be split into two groups to test two different dosages of the compound. Patients were to be treated three times per week over a period of 3 months and researchers were to monitor lung function as well as the extent and severity of infections. By administering the molecule as an inhalant, it was hoped to confine its effect to immune cells in the lung. In preliminary tests, patients with tuberculosis and asthma tolerated the inhaled gamma interferon well and there was little evidence that it was active in the bloodstream [&lt;ulink linkID="401669" linkType="Reference"&gt;401669&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Liver fibrosis/cirrhosis&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A phase II trial was initiated in January 2002 for this indication, with the aim of evaluating the safety and antifibrotic activity of gamma interferon in HCV patients who had failed standard antiviral therapy. In the AEGIS (Anti-fibrotic Efficacy Gamma Interferon Study) trial, 450 patients were randomized to receive either placebo, 100 microg of Actimmune or 200 microg of the drug three times per week via sc injection. The study was designed to evaluate the proportion of patients showing a reduction of one or more points on the fibrosis staging score following treatment with gamma interferon, compared with placebo, for 48 weeks. Trial results were expected in early 2004 [&lt;ulink linkID="435167" linkType="Reference"&gt;435167&lt;/ulink&gt;]. In October 2002, InterMune completed patient randomization of its phase II trial of Actimmune-1b injection for the treatment of severe liver fibrosis, or cirrhosis, caused by HCV. The objective of 'AEGIS' (Anti-fibrotic Efficacy Gamma Interferon Study) was to evaluate the safety and anti-fibrotic activity of Actimmune-1b in HCV patients who had failed standard antiviral therapy [&lt;ulink linkID="467698" linkType="Reference"&gt;467698&lt;/ulink&gt;]. By January 2004, Actimmune had failed to meet its primary endpoint in a phase II trial of advanced cirrhosis caused by HCV in patients who have failed antiviral therapy. The company believed that earlier intervention in milder patients over a longer period of time may have been necessary to demonstrate efficacy [&lt;ulink linkID="519793" linkType="Reference"&gt;519793&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Friedreich ataxia&lt;/subtitle&gt;In December 2015, a multicenter, single-group, open-label, phase III extension study (&lt;ulink linkID="244711" linkType="Protocol"&gt;NCT02593773&lt;/ulink&gt;; HZNP-ACT-302) evaluating Actimmune in subjects (expected n = 90) with Friedreich ataxia was initiated in the US. The trial was open to patients who participated in STEADFAST trial. The primary endpoint was the long term safety of Actimmune. At that time, the trial was expected to complete in June 2017 [&lt;ulink linkID="1759584" linkType="Reference"&gt;1759584&lt;/ulink&gt;], [&lt;ulink linkID="1759438" linkType="Reference"&gt;1759438&lt;/ulink&gt;]. In December 2016, based on the negative STEADFAST results, a decision was made to discontinue the entire Friedreich ataxia clinical program including the 26-week extension study and the long-term safety study [&lt;ulink linkID="1883711" linkType="Reference"&gt;1883711&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, a phase III trial for Friedreich ataxia was being planned [&lt;ulink linkID="1601901" linkType="Reference"&gt;1601901&lt;/ulink&gt;]. Later that month, the company planned to meet with the FDA regarding the clinical development and regulatory pathway of the drug in the fourth quarter of 2014 [&lt;ulink linkID="1601281" linkType="Reference"&gt;1601281&lt;/ulink&gt;]. In January 2015, the US FDA agreed to the primary endpoint of a randomized, double-blind, multicenter, placebo-controlled, 26-week phase III trial in Friedreich's Ataxia patients (expected n = 110). At that time, the company planned to submit an IND filing in the first quarter of 2015, and would begin enroll patients in the second quarter of 2015. The trial was expected to be completed in 18 months [&lt;ulink linkID="1625980" linkType="Reference"&gt;1625980&lt;/ulink&gt;]. In February 2015, the IND application was submitted to the US FDA. At that time,  the trial  would enroll  90 patients   and a 6-month,  open-label extension study was planned for patients completing the trial [&lt;ulink linkID="1633772" linkType="Reference"&gt;1633772&lt;/ulink&gt;]. In June 2015, the randomized, multi-center, double-blind, placebo-controlled, parallel assignment, dose-escalation, safety, efficacy and tolerability, STEADFAST trial (&lt;ulink linkID="226793" linkType="Protocol"&gt;NCT02415127&lt;/ulink&gt;; HZNP-ACT-301), was initiated in patients with Friedreich's Ataxia at four sites of the US, to evaluate the pharmacokinetic characteristics of Actimmune. At that time, the trial was expected to be completed in December 2016 [&lt;ulink linkID="1667146" linkType="Reference"&gt;1667146&lt;/ulink&gt;] [&lt;ulink linkID="1667331" linkType="Reference"&gt;1667331&lt;/ulink&gt;]. By November 2015, more than 30% of patients  have been enrolled [&lt;ulink linkID="1710869" linkType="Reference"&gt;1710869&lt;/ulink&gt;]. By February 2016, the trial had been 70% enrolled [&lt;ulink linkID="1738815" linkType="Reference"&gt;1738815&lt;/ulink&gt;]. In May 2016, target enrollment was complete with 90 patients enrolled [&lt;ulink linkID="1759438" linkType="Reference"&gt;1759438&lt;/ulink&gt;]. In December 2016, topline data from the 92-patient trial were reported. The trial did not meet either its primary endpoint of a change from baseline in the  modified FARS‐mNeuro score at 26 weeks when compared with placebo nor its secondary endpoints. At that time, based on the STEADFAST results, a decision was made to discontinue the entire Friedreich ataxia clinical program  [&lt;ulink linkID="1883711" linkType="Reference"&gt;1883711&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2013, an open-label, single group assignment, phase II study (&lt;ulink linkID="158300" linkType="Protocol"&gt;NCT01965327&lt;/ulink&gt;; 13-010121, 13-010121) was initiated in patients (expected n = 12) with Friedreich ataxia, in the US to assess the safety, tolerability and efficacy of the drug. At that time, the study was expected to be complete in August 2014 [&lt;ulink linkID="1512576" linkType="Reference"&gt;1512576&lt;/ulink&gt;]. In October 2014, data demonstrated a labeled safety profile and changes in frataxin protein levels were statistically significant in red blood cells, white blood cells and platelets. Also, statistically significant (p=0.008) mean improvement in Friedreich's Ataxia Rating Scale score was observed. The drug was found to be well tolerated. At that time, data were expected to be presented at the 139th Annual Meeting of the American Neurological Association in Baltimore, MD [&lt;ulink linkID="1601281" linkType="Reference"&gt;1601281&lt;/ulink&gt;]. By January 2015, data had shown that FARS-mNeuro score (p=0.0117) was consistent with the previously reported total FARS score (p=0.0078) [&lt;ulink linkID="1625980" linkType="Reference"&gt;1625980&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In December 2016, clinical data from a study were presented at the 58th ASH Annual Meeting and Exposition in San Diego, CA. Subjects (n = 5) received IFN-gamma-1b at single escalating doses of 10, 25, 50, and 100 microg/m2 (sc, weekly). After IFN-gamma, a peak response was observed at 12 to 24 h and then a reduction back to baseline at the lowest dose for phorbol myristate acetate (PMA). The N-formyl-methionyl-leucyl-phenylalanine (fMLF) response was found to be similar to PMA, but the early peak occurred at 8 h and returned to baseline at the lower two doses. Dose response effect was observed for peak levels achieved ranging in from 60 to 80 pg/ml at the lowest dose of IFN-gamma to 200to 600 pg/ml at the highest. With all doses of IFN, neopterin levels were peaked by 24 h and continued to remain elevated to 72 h moving back to baseline by 96 h [&lt;ulink linkID="1881763" linkType="Reference"&gt;1881763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2003,  a phase II trial for invasive aspergillosis was ongoing [&lt;ulink linkID="487490" linkType="Reference"&gt;487490&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In April 2002, InterMune and Mondobiotech designed a study to assess Actimmune's effect on the level of obstructive lung disease as measured by lung function testing and by the molecular assessment of the lung tissue. The trial would include 40 patients randomized to treatment with Actimmune or placebo [&lt;ulink linkID="447143" linkType="Reference"&gt;447143&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2001, InterMune had initiated a phase I trial in Japan  [&lt;ulink linkID="404317" linkType="Reference"&gt;404317&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Connetics (now Stiefel Laboratories, a subsidiary of &lt;ulink linkID="28355" linkType="Company"&gt;&lt;/ulink&gt;GSK)  initiated a 40 patient phase II trial of gamma interferon in keloid scarring in January 1997. Enrollment was complete in May 1997 [&lt;ulink linkID="230951" linkType="Reference"&gt;230951&lt;/ulink&gt;], [&lt;ulink linkID="246019" linkType="Reference"&gt;246019&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Other potential indications, such as infection in patients suffering from immunosuppression and dysfunction of the immune system, were being studied in a clinical trial program [&lt;ulink linkID="178550" linkType="Reference"&gt;178550&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 1992, Boehringer Ingelheim conducted clinical trials for the use of Actimmune against visceral leishmaniasis as part of the WHO's program for Research and Training in Tropical Diseases (TDR) [&lt;ulink linkID="178570" linkType="Reference"&gt;178570&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2015, preclinical data were presented at the 97th Annual Meeting and Exposition of the Endocrine Society in San Diego, CA. IFN-gamma-1b significantly attenuated the increase of whole body areal BMD and significantly reduced bone volume over tissue volume gain in the ADO2 knock-in (G213R mutation in Clcn7) mice [&lt;ulink linkID="1639715" linkType="Reference"&gt;1639715&lt;/ulink&gt;], [&lt;ulink linkID="1639627" linkType="Reference"&gt;1639627&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2002, InterMune and Maxygen were investigating next-generation version of gamma interferon that could be taken once weekly rather than three times a week, presumably for both CGD and osteopetrosis. Maxygen developed a series of preclinical candidates that demonstrated, in animal models, to have improved pharmacokinetic properties that should allow a once-per-week dosing regimen [&lt;ulink linkID="466030" linkType="Reference"&gt;466030&lt;/ulink&gt;], [&lt;ulink linkID="468282" linkType="Reference"&gt;468282&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Idiopathic pulmonary fibrosis&lt;/subtitle&gt;By April 2006, Intermune had conducted preclinical studies examining the effects of Actimmune in combination with &lt;ulink linkID="7871" linkType="Drug"&gt;pirfenidone&lt;/ulink&gt;; presentation of the data was expected in May 2006 [&lt;ulink linkID="664462" linkType="Reference"&gt;664462&lt;/ulink&gt;]. In October 2006, data was presented at CHEST 2006 in Salt Lake City, UT. In vitro studies using human fibroblast pretreated with Actimmune and pirfenidone and stimulated with transforming growth factor-beta showed both drugs inhibited fibrotic pathways and when combined induced an additive suppressive effect [&lt;ulink linkID="734098" linkType="Reference"&gt;734098&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2005, multiple studies of Actimmune were presented at the annual International Conference of the American Thoracic Society in San Diego, CA. Preclinical in vitro data showed Actimmune inhibited IL-4 upregulation in purified CD4 T-cells from healthy volunteers, and IL-4-induced collagen synthesis in human lung fibroblasts. Clinical data was also presented [&lt;ulink linkID="603283" linkType="Reference"&gt;603283&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2004, data, which assessed the effect of Actimmune in vitro cellular models of lung fibrosis, was presented at the 70th ACCP annual meeting in Seattle, WA. Results indicated that at test concentrations similar to post-dose human serum concentrations of interferon gamma-1b, the drug inhibited both TGF-beta-induced collagen synthesis and TGF-beta-induced accumulation of TIMP1, and therefore might affect a substantial decrease in the rate of extracellular matrix accumulation [&lt;ulink linkID="567502" linkType="Reference"&gt;567502&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cryptococcal meningitis&lt;/subtitle&gt;Preclinical data from mouse models of cryptococcal fungal infection was published in September 2000 showing that combination therapy cured 78% of infected mice, compared with 10% with amphotericin B alone [&lt;ulink linkID="404317" linkType="Reference"&gt;404317&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Fungal infection&lt;/subtitle&gt;By April 1999, fungal infection was being investigated [&lt;ulink linkID="597107" linkType="Reference"&gt;597107&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1062207">Clinigen Group plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2014-09-19T00:00:00.000Z</StatusDate><Source id="1595745" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2014-09-19T00:00:00.000Z</StatusDate><Source id="1595745" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062207">Clinigen Group plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062207">Clinigen Group plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062207">Clinigen Group plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062207">Clinigen Group plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-04-28T00:00:00.000Z</StatusDate><Source id="1958597" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2015-12-14T00:00:00.000Z</StatusDate><Source id="1721034" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1766">Renal cell carcinoma</Indication><StatusDate>2015-12-14T00:00:00.000Z</StatusDate><Source id="1721034" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3466">Metastatic bladder cancer</Indication><StatusDate>2015-12-14T00:00:00.000Z</StatusDate><Source id="1721034" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062207">Clinigen Group plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1062207">Clinigen Group plc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2006-02-02T00:00:00.000Z</StatusDate><Source id="648407" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="201">Liver disease</Indication><StatusDate>2006-05-02T00:00:00.000Z</StatusDate><Source id="519793" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2006-02-02T00:00:00.000Z</StatusDate><Source id="648407" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15530">Connetics Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="95">Dermatological disease</Indication><StatusDate>1997-08-01T00:00:00.000Z</StatusDate><Source id="260711" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2007-03-06T00:00:00.000Z</StatusDate><Source id="770946" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="2974">Friedreich ataxia</Indication><StatusDate>2016-12-08T00:00:00.000Z</StatusDate><Source id="1883711" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15530">Connetics Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1102">Atopic dermatitis</Indication><StatusDate>1997-08-01T00:00:00.000Z</StatusDate><Source id="260711" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2007-03-06T00:00:00.000Z</StatusDate><Source id="770946" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="999">Renal tumor</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="215707" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2004-03-12T00:00:00.000Z</StatusDate><Source id="1137480" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2007-03-06T00:00:00.000Z</StatusDate><Source id="770946" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29586">Relief Therapeutics Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29586">Relief Therapeutics Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2003-10-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2003-10-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2017-11-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24820">Maxygen LLC</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2007-09-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-11-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>2004-09-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="218">Mycobacterium infection</Indication><StatusDate>2004-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2002-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1813">Cryptococcus neoformans meningitis</Indication><StatusDate>2004-09-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="221">Mycobacterium tuberculosis infection</Indication><StatusDate>2004-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="197">Leishmania tropica infection</Indication><StatusDate>1994-06-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2012-06-19T00:00:00.000Z</StatusDate><Source id="1302611" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15530">Connetics Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1999-04-30T00:00:00.000Z</StatusDate><Source id="597107" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2012-06-19T00:00:00.000Z</StatusDate><Source id="1302611" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2012-06-19T00:00:00.000Z</StatusDate><Source id="1302611" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1999-01-31T00:00:00.000Z</StatusDate><Source id="1997927" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="95">Dermatological disease</Indication><StatusDate>1996-12-15T00:00:00.000Z</StatusDate><Source id="1997934" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19453">Genentech Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1997855" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1053335">Horizon Pharma plc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2057135" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26430">InterMune Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2012-06-19T00:00:00.000Z</StatusDate><Source id="1302611" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29586">Relief Therapeutics Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2011-12-23T00:00:00.000Z</StatusDate><Source id="1250837" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2001-01-05T00:00:00.000Z</StatusDate><Source id="394975" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2001-01-05T00:00:00.000Z</StatusDate><Source id="394975" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1992-10-28T00:00:00.000Z</StatusDate><Source id="1420999" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1992-09-24T00:00:00.000Z</StatusDate><Source id="1429015" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>1999-02-25T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1067362">Vidara Therapeutics LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2974">Friedreich ataxia</Indication><StatusDate>2013-08-31T00:00:00.000Z</StatusDate><Source id="1512576" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1067362">Vidara Therapeutics LLC</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2012-06-19T00:00:00.000Z</StatusDate><Source id="1302611" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1067362">Vidara Therapeutics LLC</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2012-06-19T00:00:00.000Z</StatusDate><Source id="1302611" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1067362">Vidara Therapeutics LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2012-06-19T00:00:00.000Z</StatusDate><Source id="1302611" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1067362">Vidara Therapeutics LLC</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2012-06-19T00:00:00.000Z</StatusDate><Source id="1302611" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2974">Friedreich ataxia</Indication><StatusDate>2014-09-19T00:00:00.000Z</StatusDate><Source id="1595745" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1999-12-09T00:00:00.000Z</StatusDate><Source id="1685979" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1992-12-24T00:00:00.000Z</StatusDate><Source id="1420999" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1992-12-24T00:00:00.000Z</StatusDate><Source id="1429016" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2974">Friedreich ataxia</Indication><StatusDate>2015-06-05T00:00:00.000Z</StatusDate><Source id="1667146" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="999">Renal tumor</Indication><StatusDate>1993-12-31T00:00:00.000Z</StatusDate><Source id="1997841" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1989-12-20T00:00:00.000Z</StatusDate><Source id="1997827" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1990-12-21T00:00:00.000Z</StatusDate><Source id="1997830" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19453">Genentech Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1991-04-18T00:00:00.000Z</StatusDate><Source id="1997837" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15530">Connetics Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="95">Dermatological disease</Indication><StatusDate>1996-12-15T00:00:00.000Z</StatusDate><Source id="1997934" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1990-12-31T00:00:00.000Z</StatusDate><Source id="1997855" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1999-04-30T00:00:00.000Z</StatusDate><Source id="597107" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>1999-08-23T00:00:00.000Z</StatusDate><Source id="337568" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>1999-04-30T00:00:00.000Z</StatusDate><Source id="597107" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29586">Relief Therapeutics Holding AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2012-01-31T00:00:00.000Z</StatusDate><Source id="1261324" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1813">Cryptococcus neoformans meningitis</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate><Source id="487490" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1992-12-07T00:00:00.000Z</StatusDate><Source id="1998485" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>1992-12-07T00:00:00.000Z</StatusDate><Source id="1998485" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>1999-02-25T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate>2017-08-07T00:00:00.000Z</StatusDate><Source id="1951905" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2017-06-30T00:00:00.000Z</StatusDate><Source id="1997782" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1265">Osteopetrosis</Indication><StatusDate>2014-09-19T00:00:00.000Z</StatusDate><Source id="1595745" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1053335">Horizon Pharma plc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="3074">Chronic granulomatous disease</Indication><StatusDate>2014-09-19T00:00:00.000Z</StatusDate><Source id="1595745" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15530">Connetics Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="95">Dermatological disease</Indication><StatusDate>1997-01-30T00:00:00.000Z</StatusDate><Source id="230951" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15530">Connetics Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>1996-09-26T00:00:00.000Z</StatusDate><Source id="220146" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15530">Connetics Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate>1996-12-15T00:00:00.000Z</StatusDate><Source id="1997934" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2002-02-06T00:00:00.000Z</StatusDate><Source id="438505" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2000-09-27T00:00:00.000Z</StatusDate><Source id="383530" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="201">Liver disease</Indication><StatusDate>2002-01-09T00:00:00.000Z</StatusDate><Source id="435167" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate><Source id="487490" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="218">Mycobacterium infection</Indication><StatusDate>1999-08-23T00:00:00.000Z</StatusDate><Source id="337433" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>1999-08-23T00:00:00.000Z</StatusDate><Source id="337433" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1813">Cryptococcus neoformans meningitis</Indication><StatusDate>2000-02-04T00:00:00.000Z</StatusDate><Source id="354281" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2003-12-16T00:00:00.000Z</StatusDate><Source id="517268" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2003-12-16T00:00:00.000Z</StatusDate><Source id="517268" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2000-10-30T00:00:00.000Z</StatusDate><Source id="387351" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2002-04-11T00:00:00.000Z</StatusDate><Source id="447143" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="88">Cystic fibrosis</Indication><StatusDate>2001-03-01T00:00:00.000Z</StatusDate><Source id="400450" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="197">Leishmania tropica infection</Indication><StatusDate>1992-12-01T00:00:00.000Z</StatusDate><Source id="178570" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29586">Relief Therapeutics Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2002-04-11T00:00:00.000Z</StatusDate><Source id="447143" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24820">Maxygen LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2002-10-08T00:00:00.000Z</StatusDate><Source id="466030" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>1999-11-08T00:00:00.000Z</StatusDate><Source id="346608" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><StatusDate>2000-05-04T00:00:00.000Z</StatusDate><Source id="365022" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26430">InterMune Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="218">Mycobacterium infection</Indication><StatusDate>1999-04-30T00:00:00.000Z</StatusDate><Source id="597107" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1053335">Horizon Pharma plc</OwnerCompany><Country id="US">US</Country><Indication id="2974">Friedreich ataxia</Indication><AwardedIndication>Treatment of Friedreich ataxia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-04-10T00:00:00.000Z</MileStoneDate><Source id="1649719" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1053335">Horizon Pharma plc</OwnerCompany><Country id="US">US</Country><Indication id="2974">Friedreich ataxia</Indication><AwardedIndication>Treatment of Friedreich ataxia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate>2015-02-13T00:00:00.000Z</MileStoneDate><Source id="1633772" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="26430">InterMune Inc</OwnerCompany><Country id="US">US</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis (IPF)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2002-01-07T00:00:00.000Z</MileStoneDate><Source id="434993" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1053335">Horizon Pharma plc</OwnerCompany><Country id="US">US</Country><Indication id="2974">Friedreich ataxia</Indication><AwardedIndication>Treatment of Friedreich's Ataxia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2014-10-01T00:00:00.000Z</MileStoneDate><Source id="1599736" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29586">Relief Therapeutics Holding AG</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2012-08-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29586">Relief Therapeutics Holding AG</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-10-29T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="19453">Genentech Inc</OwnerCompany><Country id="US">US</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2007-10-11T00:00:00.000Z</MileStoneDate><Source id="507427" type="OTHER"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29586">Relief Therapeutics Holding AG</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2007-09-12T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26430">InterMune Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate>2007-05-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26430">InterMune Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate>2006-09-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26430">InterMune Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2005-07-04T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26430">InterMune Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2005-05-27T00:00:00.000Z</MileStoneDate><Source id="1260550" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="26430">InterMune Inc</OwnerCompany><Country id="US">US</Country><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><AwardedIndication>Treatment of idiopathic pulmonary fibrosis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2002-12-09T00:00:00.000Z</MileStoneDate><Source id="1316446" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14881">Boehringer Ingelheim International GmbH</OwnerCompany><Country id="TW">Taiwan</Country><Indication id="3074">Chronic granulomatous disease</Indication><AwardedIndication>Treatment of chronic granulomatous disease</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1999-12-09T00:00:00.000Z</MileStoneDate><Source id="1685979" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1053335">Horizon Pharma plc</OwnerCompany><Country id="US">US</Country><Indication id="1265">Osteopetrosis</Indication><AwardedIndication>Delaying time to disease progression in patients with severe, malignant osteopetrosis.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1996-09-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1053335">Horizon Pharma plc</OwnerCompany><Country id="US">US</Country><Indication id="999">Renal tumor</Indication><AwardedIndication>Treatment of renal cell carcinoma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1995-12-04T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1053335">Horizon Pharma plc</OwnerCompany><Country id="US">US</Country><Indication id="3074">Chronic granulomatous disease</Indication><AwardedIndication>Treatment of chronic granulomatous disease.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1988-09-30T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00985"><Name>IL-4 receptor</Name><SwissprotNumbers><Swissprot>P16382</Swissprot><Swissprot>P24394</Swissprot><Swissprot>Q63257</Swissprot><Swissprot>Q6WG24</Swissprot><Swissprot>Q863Z5</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01832"><Name>TGF beta receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-09261"><Name>Interferon gamma ligand</Name><SwissprotNumbers><Swissprot>A4PIZ9</Swissprot><Swissprot>O35497</Swissprot><Swissprot>O35735</Swissprot><Swissprot>O57571</Swissprot><Swissprot>O57603</Swissprot><Swissprot>O57608</Swissprot><Swissprot>O73915</Swissprot><Swissprot>O77763</Swissprot><Swissprot>P01579</Swissprot><Swissprot>P01580</Swissprot><Swissprot>P01581</Swissprot><Swissprot>P07353</Swissprot><Swissprot>P17773</Swissprot><Swissprot>P17803</Swissprot><Swissprot>P28333</Swissprot><Swissprot>P28341</Swissprot><Swissprot>P30123</Swissprot><Swissprot>P42160</Swissprot><Swissprot>P42161</Swissprot><Swissprot>P42162</Swissprot><Swissprot>P46402</Swissprot><Swissprot>P49708</Swissprot><Swissprot>P63309</Swissprot><Swissprot>P63310</Swissprot><Swissprot>P63311</Swissprot><Swissprot>P79154</Swissprot><Swissprot>Q1WM28</Swissprot><Swissprot>Q25BC0</Swissprot><Swissprot>Q2PE75</Swissprot><Swissprot>Q4ZH68</Swissprot><Swissprot>Q5CCK0</Swissprot><Swissprot>Q5I6S9</Swissprot><Swissprot>Q62574</Swissprot><Swissprot>Q647G2</Swissprot><Swissprot>Q7TSP4</Swissprot><Swissprot>Q865W6</Swissprot><Swissprot>Q865X1</Swissprot><Swissprot>Q865Y4</Swissprot><Swissprot>Q866Y6</Swissprot><Swissprot>Q8MKF5</Swissprot><Swissprot>Q8SPW9</Swissprot><Swissprot>Q9QXX2</Swissprot><Swissprot>Q9TTB0</Swissprot><Swissprot>Q9TV67</Swissprot><Swissprot>Q9YGB9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2123932" linkType="reference" linkID="2123932"&gt;2123932&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1053335">Horizon Pharma plc</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="1053730">Friedreich's Ataxia Research Alliance</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1062207">Clinigen Group plc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1067362">Vidara Therapeutics LLC</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="1103591">Centurion Pharma</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14109">Amgen Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14881">Boehringer Ingelheim International GmbH</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>6</CountTotal></Company><Company><Company id="19446">Roche Holding AG</Company><CountAsPrincipalActive>4</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>4</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>9</CountTotal></Company><Company><Company id="21112">Fox Chase Cancer Center</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24820">Maxygen LLC</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28355">GlaxoSmithKline plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29586">Relief Therapeutics Holding AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>2</CountActive><CountInactive>2</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>5</CountActive><CountInactive>0</CountInactive><CountTotal>5</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="113247" title="Intermune to develop Genentech's Actimmune     "/><Deal id="113248" title="Connetics to market Genentech's Actimmune in US for CGD and develop for other indications    "/><Deal id="113268" title="InterMune and BI to codevelop Imukin outside of US, Canada, and Japan for several indications "/><Deal id="116215" title="InterMune and Mondobiotech to collaborate on Actimmune R&amp;D for asthma"/><Deal id="116216" title="Maxygen to develop once weekly formulation of Actimmune for InterMune"/><Deal id="139368" title="Vidara to acquire InterMune's Actimmune"/><Deal id="151214" title="Horizon and Friedreich's Ataxia Research Alliance to develop Actimmune against Friedreich's ataxia"/><Deal id="151957" title="Centurion to develop and distribute THERAMetrics' Interferon Gamma against IPF and Aviptadil against cystic fibrosis and sarcoidosis in Turkey and MENA       "/><Deal id="155531" title="Fox Chase Cancer Center to study Horizon Pharma's Actimmune in combination with PD-1/PD-L1 inhibitors against cancers "/><Deal id="157284" title="Boehringer Ingelheim to manufacture and supply Actimmune to Vidara "/><Deal id="157293" title="Vidara to commercialize Boehringer Ingelheim's Actimmune in Latin America, Asia, Africa and Eastern Europe  "/><Deal id="160508" title="Horizon Pharma acquires Actimmune rights from Boehringer Ingelheim worldwide except US, Canada and Japan     "/><Deal id="160513" title="Horizon Pharma to license patent from an undisclosed company related to Actimmune against Friedreich ataxia  "/><Deal id="242017" title="Data and manufacture of Actimmune"/><Deal id="242258" title="Interferon gamma-1b patents"/><Deal id="245636" title="BI and Genentech to develop actimmune against chronic granulomatous disease in Europe"/><Deal id="248626" title="Clinigen acquired Horizon's Imukin for CGD and SMO worldwide excluding the US, Canada and Japan   "/></Deals><PatentFamilies><PatentFamily id="1141737" number="WO-2005067963" title="Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens"/><PatentFamily id="1159745" number="WO-00149260" title="Gamma-Ifn Liquid-Droplet Aerosol And Method"/><PatentFamily id="1196279" number="WO-08504186" title="A Modified Gamma Interferon, DNA Sequences Encoding It And Processes For Producing It"/><PatentFamily id="1196925" number="EP-00088540" title="DNA Sequences, Recombinant DNA Molecules And Processes For Producing Human Immune Interferon-Like Polypeptides"/><PatentFamily id="1215041" number="WO-2004069199" title="Marketing system for improving patient compliance and methods and devices relating to same"/><PatentFamily id="1242987" number="WO-2005123113" title="Interferon compositions and methods of use thereof."/><PatentFamily id="1464393" number="WO-2004019758" title="Methods of treating idiopathic pulmonary fibrosis"/><PatentFamily id="1492244" number="WO-08304053" title="Manufacture and expression of large structural genes."/><PatentFamily id="1584432" number="WO-03007981" title="Methods of treating liver fibrosis"/><PatentFamily id="1841323" number="WO-2006016930" title="Methods for treating HCV infection"/><PatentFamily id="1936645" number="EP-00077670" title="Human Immune Interferon."/><PatentFamily id="1990498" number="WO-2004078194" title="Interferon drug therapy for the treatment of viral diseases and liver fibrosis"/><PatentFamily id="2038046" number="JP-2003261600" title="Interferon-(gamma) and its purification method"/><PatentFamily id="204910" number="WO-2004089283" title="Compositions and methods for treating viral infections"/><PatentFamily id="2159238" number="EP-00146354" title="Recombinant gamma interferons and pharmaceutical compositions containing them"/><PatentFamily id="2789490" number="US-20140244228" title="Codon optimization of a synthetic gene(s) for protein expression"/><PatentFamily id="3122119" number="KR-01675521" title="The method for controlling the expression of the interferon-gamma by using the indole amine 2,3- dioxygenase."/><PatentFamily id="3523106" number="WO-2017015442" title="Combination of immunomodulatory agent with PD-1-or PD-L1 checkpoint inhibitors in the treatment of cancer"/><PatentFamily id="656161" number="WO-2005038056" title="Combination therapy for the treatment of viral diseases"/><PatentFamily id="721914" number="WO-09951260" title="Treatment of cardiac hypertrophy."/><PatentFamily id="910370" number="WO-09426302" title="Stable Liquid Compositions Of Gamma Interferon"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biogen Inc" id="1005244"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dr Rentschler Holding GmbH &amp; Co KG" id="1034882"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Horizon Pharma plc" id="1053335"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bausch Health Companies Inc" id="17058"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"/><CountAsOwner>15</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>15</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fox Chase Cancer Center" id="21112"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Relief Therapeutics Holding AG" id="29586"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug><Drug id="50408"><DrugName>SF-1126</DrugName><DrugNamesKey><Name id="42809401">Interceptors</Name></DrugNamesKey><DrugSynonyms><Name><Value>SF-1126</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Interceptors</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>PI3K inhibitors (cancer), Semafore</Value></Name><Name><Value>RGD-SF-1126</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>SF-1174</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PI3K inhibitors (cancer), SignalRx</Value></Name><Name><Value>multi-kinase inhibitor (cancer), SignalRx</Value></Name></DrugSynonyms><CompanyOriginator id="1003729">Semafore Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="1087306">SignalRx Pharmaceuticals Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1003729">Semafore Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="50408" type="Drug"><TargetEntity id="385711" type="siDrug">SF-1126</TargetEntity></SourceEntity><SourceEntity id="1003729" type="Company"><TargetEntity id="4297084940" type="organizationId">Semafore Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1087306" type="Company"><TargetEntity id="5040241175" type="organizationId">SignalRx Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"/><TargetEntity id="690" type="siCondition"/></SourceEntity><SourceEntity id="1828" type="ciIndication"><TargetEntity id="C90.0" type="ICD10"/><TargetEntity id="10028228" type="MEDDRA"/><TargetEntity id="D009101" type="MeSH"/><TargetEntity id="29073" type="ORPHANET"/><TargetEntity id="-18870694" type="omicsDisease"/><TargetEntity id="710" type="siCondition"/></SourceEntity><SourceEntity id="2726" type="ciIndication"><TargetEntity id="10029260" type="MEDDRA"/><TargetEntity id="D009447" type="MeSH"/><TargetEntity id="635" type="ORPHANET"/><TargetEntity id="-2062438551" type="omicsDisease"/><TargetEntity id="712" type="siCondition"/></SourceEntity><SourceEntity id="307" type="ciIndication"><TargetEntity id="10041823" type="MEDDRA"/><TargetEntity id="D002294" type="MeSH"/><TargetEntity id="-1612557995" type="omicsDisease"/><TargetEntity id="676" type="siCondition"/></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"/><TargetEntity id="D008228" type="MeSH"/><TargetEntity id="547" type="ORPHANET"/><TargetEntity id="-1008757452" type="omicsDisease"/><TargetEntity id="703" type="siCondition"/></SourceEntity><SourceEntity id="3673" type="ciIndication"><TargetEntity id="5572" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="76090" type="Action"><TargetEntity id="3739" type="Mechanism">mTOR Complex 1 (mTORC1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4536" type="Action"><TargetEntity id="5159" type="Mechanism">Serine/threonine-protein kinase PLK1 (PLK-1; STPK13) Inhibitors</TargetEntity><TargetEntity id="1916" type="Mechanism">Polo-like Kinase-1 (Plk-1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="25889" type="Action"><TargetEntity id="1497" type="Mechanism">DNA-Dependent Protein Kinase (DNA-PK) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4528" type="Action"><TargetEntity id="3101" type="Mechanism">Pim-1 Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1575" type="Action"><TargetEntity id="465" type="Mechanism">Phosphatidylinositol 3-Kinase (PI3K) Inhibitors</TargetEntity><TargetEntity id="3512" type="Mechanism">Inositol Phosphate Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="76096" type="Action"><TargetEntity id="3740" type="Mechanism">mTOR Complex 2 (mTORC2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01553" type="ciTarget"><TargetEntity id="59541" type="siTarget">Phosphatidylinositol 3-kinase (PI3K) (nonspecified subtype)</TargetEntity></SourceEntity><SourceEntity id="PTGT-01570" type="ciTarget"><TargetEntity id="190103944952923" type="siTarget">Serine/threonine-protein kinase pim-1</TargetEntity><TargetEntity id="622" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01588" type="ciTarget"><TargetEntity id="56397273553473" type="siTarget">Serine/threonine-protein kinase PLK1</TargetEntity><TargetEntity id="2637" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-05364" type="ciTarget"><TargetEntity id="160911" type="siTarget">DNA-Dependent Protein Kinase (DNA-PK)</TargetEntity></SourceEntity><SourceEntity id="PTGT-13173" type="ciTarget"><TargetEntity id="123271" type="siTarget">mTOR complex 1</TargetEntity></SourceEntity><SourceEntity id="PTGT-13174" type="ciTarget"><TargetEntity id="123281" type="siTarget">mTOR complex 2</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1828">Multiple myeloma</Indication><Indication id="2726">Neuroblastoma</Indication><Indication id="307">Squamous cell carcinoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3673">Metastatic head and neck cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="1575">Phosphoinositide 3-kinase inhibitor</Action><Action id="25889">DNA dependent protein kinase inhibitor</Action><Action id="4528">PIM-1 protein kinase inhibitor</Action><Action id="76090">mTOR complex 1 inhibitor</Action><Action id="76096">mTOR complex 2 inhibitor</Action><Action id="4536">Polo-like kinase 1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="61">Angiogenesis inhibitor</Action><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="207">Protein conjugated</Technology><Technology id="1672">Directed prodrug therapy</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology></Technologies><LastModificationDate>2019-06-30T10:13:15.000Z</LastModificationDate><ChangeDateLast>2019-07-01T00:00:00.000Z</ChangeDateLast><AddedDate>2004-06-10T16:43:08.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1087306" linkType="Company"&gt;SignalRx Pharmaceuticals&lt;/ulink&gt;, under license from  &lt;ulink linkID="1003729" linkType="Company"&gt;Semafore Pharmaceuticals&lt;/ulink&gt;, is developing SF-1126 (structure shown), a prodrug composed of  the  PI3K and mTOR complex-1 and 2 inhibitor    &lt;ulink linkID="8278" linkType="Drug"&gt;LY-294002&lt;/ulink&gt;  (SF-1101) conjugated to the vascular-targeting tetrapeptide SF-1174, that inhibit pan-PI3K (alpha, beta, gamma, and delta isoforms), DNA-PK, PIM1, and PLK1, for the potential iv treatment of cancer [&lt;ulink linkID="543627" linkType="reference"&gt;543627&lt;/ulink&gt;], [&lt;ulink linkID="544080" linkType="reference"&gt;544080&lt;/ulink&gt;], [&lt;ulink linkID="544210" linkType="reference"&gt;544210&lt;/ulink&gt;], [&lt;ulink linkID="1244153" linkType="Reference"&gt;1244153&lt;/ulink&gt;], [&lt;ulink linkID="1499006" linkType="Reference"&gt;1499006&lt;/ulink&gt;]. In December 2016, a phase II trial for metastatic squamous neck cancer with occult primary squamous cell carcinoma was initiated [&lt;ulink linkID="1728115" linkType="Reference"&gt;1728115&lt;/ulink&gt;]. A phase I trial for multiple myeloma (MM) began in January 2008 [&lt;ulink linkID="865394" linkType="Reference"&gt;865394&lt;/ulink&gt;]; in February 2010, the trial  protocol was expanded to include patients with B-cell malignancies, including  chronic lymphocytic lymphoma (CLL) and non-Hodgkin's lymphoma (NHL) [&lt;ulink linkID="1076548" linkType="Reference"&gt;1076548&lt;/ulink&gt;]. In July 2015, a phase I trial for relapsed or refractory neuroblastoma was  initiated [&lt;ulink linkID="1626944" linkType="Reference"&gt;1626944&lt;/ulink&gt;]; in October 2017, phase I development in this setting was ongoing [&lt;ulink linkID="1968747" linkType="Reference"&gt;1968747&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In November 2010, the  FDA granted Orphan Drug status for CLL [&lt;ulink linkID="1146514" linkType="Reference"&gt;1146514&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In December 2015, an open-label, single group assignment, phase II trial (&lt;ulink linkID="249834" linkType="Protocol"&gt;NCT02644122&lt;/ulink&gt;; 140904) in metastatic squamous neck cancer with occult primary squamous cell carcinoma patients (expected n = 29) with mutations in PIK3CA gene and/or PI3 kinase pathway genes was planned to assess the safety and efficacy of SF-1126. The trial was initiated in the US in December 2016, and at that time was expected to complete in April 2022 [&lt;ulink linkID="1728115" linkType="Reference"&gt;1728115&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; By October 2012, pediatric trials for neuroblastoma and other embryonal tumors were planned [&lt;ulink linkID="1330517" linkType="Reference"&gt;1330517&lt;/ulink&gt;]; in November 2013, SignalRx was planning for phase II trial in adult cancer patients and a dose-escalating phase Ib trial in pediatric cancer patients [&lt;ulink linkID="1499006" linkType="Reference"&gt;1499006&lt;/ulink&gt;]. In January 2015, an open-label, single group assignment, phase I trial (&lt;ulink linkID="219884" linkType="Protocol"&gt;NCT02337309&lt;/ulink&gt;; NANT 2014-01, N14-01) was scheduled to begin later that month, in the US and Canada, in pediatric patients (expected n = 28 ) with relapsed or refractory neuroblastoma, to assess the safety of SF-1126. At that time, the trial was expected to complete in June 2018. In July 2015, the trial was initiated in the US. In September 2017, enrollment was ongoing  [&lt;ulink linkID="1626944" linkType="Reference"&gt;1626944&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2010, Semafore was planning to initiate combination trials once phase I monotherapy studies had been completed [&lt;ulink linkID="1076548" linkType="Reference"&gt;1076548&lt;/ulink&gt;]. In February 2010, once single-agent, phase I studies had been completed, the company was planning to initiate combination studies in the 'near future' [&lt;ulink linkID="1076548" linkType="Reference"&gt;1076548&lt;/ulink&gt;]. In November 2011, it was reported at the CHI's Second Annual Advances in Targeting PI3K Pathways Meeting in Boston, MA, that a clinical benefit had been observed against B cell malignancies when SF-1126 was used in combination with &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; [&lt;ulink linkID="1240909" linkType="Reference"&gt;1240909&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;A phase I trial for MM began in January 2008. The North American, dose-escalating, multiple-dose trial would enroll up to 30 patients who had failed at least two prior treatments [&lt;ulink linkID="865394" linkType="Reference"&gt;865394&lt;/ulink&gt;]. In February 2010, the study protocol was amended to include patients with B-cell malignancies, including indolent  NHL and CLL [&lt;ulink linkID="1076548" linkType="Reference"&gt;1076548&lt;/ulink&gt;]. In June 2010, preliminary results from two CLL patients were presented at Cambridge Healthtech Institute's Eighth Annual Next-Gen Kinase Inhibitors Oncology &amp;amp; Beyond Conference in Cambridge, MA, showing suggestions of clinical activity [&lt;ulink linkID="1109766" linkType="Reference"&gt;1109766&lt;/ulink&gt;]. In November 2010, interim data were expected to be presented at the 52nd ASH annual meeting in Orlando, FL in December 2010 [&lt;ulink linkID="1146514" linkType="Reference"&gt;1146514&lt;/ulink&gt;]. In August 2012, similar data were published. Stable disease was observed in 19 of 38 (58%) patients and the drug was found to reduce p-AKT and induce apoptosis [&lt;ulink linkID="1353806" linkType="Reference"&gt;1353806&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006, the company expected to begin phase I trials later that year [&lt;ulink linkID="656257" linkType="Reference"&gt;656257&lt;/ulink&gt;]. In December 2006, a phase I solid tumor trial and a phase I MM trial were to start in 2007 [&lt;ulink linkID="748502" linkType="Reference"&gt;748502&lt;/ulink&gt;], [&lt;ulink linkID="755384" linkType="Reference"&gt;755384&lt;/ulink&gt;]. A phase I trial began in March 2007. The open-label, ascending-dose trial would assess safety, pharmacokinetics and pharmacodynamics in patients with relapsed solid cancers [&lt;ulink linkID="777750" linkType="Reference"&gt;777750&lt;/ulink&gt;]. Interim data were reported in June 2008. In the multicenter, dose-cohort escalating trial, patients received SF-1126 twice-weekly as an iv infusion for 4 weeks in a 28-day cycle. Stable disease was observed in 3 of 12 patients who had completed one cycle of treatment. The drug was well tolerated and all adverse events were non-cumulative and reversible. At that time, enrollment was expected to be completed by the fourth quarter of 2008 [&lt;ulink linkID="913357" linkType="Reference"&gt;913357&lt;/ulink&gt;]. In May  2009,  further clinical data were presented at the 45th ASCO meeting in Orlando, FL. In the study, patients (n = 36) received 90, 140 180, 240, 320, 430 and 630 mg/m2 iv infusion SF-1126 twice weekly.  Preliminary results showed that the compound was well-tolerated, the MTD was not reached. A total of 16 patients showed stable disease after a median duration of 12 weeks.  [&lt;ulink linkID="1007741" linkType="Reference"&gt;1007741&lt;/ulink&gt;], [&lt;ulink linkID="1014091" linkType="Reference"&gt;1014091&lt;/ulink&gt;]. In December 2009, further data from this trial were presented at the 51st ASH meeting in New Orleans, LA. Adverse effects were of Grade 1 or 2 severity and manageable, with the most common  events being   nausea, allergic reaction and vomiting. Pharmacodynamic analyses revealed  reductions in biomarkers of PI3K pathway activity in marrow plasma cells. Pharmacokinetic analyses showed that the maximum concentration and exposure of SF-1126 increased with doses &amp;gt;/= 140 mg/m2, achieving   efficacious doses in animal xenograft models of MM.The study was being completed at the 1110 mg/m2 dose of SF-1126 and planning  was ongoing for  a further trial combining SF-1126 with other anti-myeloma agents [&lt;ulink linkID="1062721" linkType="Reference"&gt;1062721&lt;/ulink&gt;]. Similar data were also presented in November 2010 at CHI's Inaugural Targeting the PI3K Pathway meeting in Boston, MA [&lt;ulink linkID="1149941" linkType="Reference"&gt;1149941&lt;/ulink&gt;]. In June 2011, similar clinical data were presented at the 47th ASCO meeting in Chicago, IL [&lt;ulink linkID="1195393" linkType="Reference"&gt;1195393&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;By February 2004, an IND filing was expected in the second half of 2005 [&lt;ulink linkID="543627" linkType="reference"&gt;543627&lt;/ulink&gt;], [&lt;ulink linkID="544080" linkType="reference"&gt;544080&lt;/ulink&gt;], [&lt;ulink linkID="544210" linkType="reference"&gt;544210&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2012, preclinical data presented at CHI's Third Annual Advances in Targeting the PI3K Pathway Meeting, Boston, MA, indicated that SF-1126 elicited superior inhibition of leukemic B-cell proliferation in diffuse large B-cell lymphoma cell lines compared with idelalisib. The mechanism was thought to be via PIM1 inhibition, which is over-expressed in these cell lines [&lt;ulink linkID="1330517" linkType="Reference"&gt;1330517&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, preclinical data were presented at the 53rd ASH meeting in San Diego, CA. SF-1126 and &lt;ulink linkID="48319" linkType="Drug"&gt;idelalisib&lt;/ulink&gt;, a PI3K delta-specific inhibitor showed antiproliferative activity in aggressive B-NHL cell lines, and induced G1 arrest in SUDHL-4 cells. In SUDHL-4, TMD-8 and additional aggressive B-NHL cells, SF-1126 and idelalisib induced apoptosis. In several B-NHL cell lines and in TMD-8 cells, SF-1126 showed induction of PARP-cleavage in a dose-dependent manner; this induction of dose-dependent PARP-cleavage by SF-1126 was superior to idelalisib in inducing apoptosis. In aggressive B-NHL cells, rituximab enhanced SF-1126- and idelalisib-induced apoptosis. In B-NHL cells, SF-1126 (5 to 50 microM) decreased cyclin D1 and potently inhibited phosphorylation of AKT and  glycogen synthase kinase-3 beta in a dose-dependent manner [&lt;ulink linkID="1244153" linkType="Reference"&gt;1244153&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In November 2010, preclinical data were presented CHI's Inaugural Targeting the PI3K Pathway meeting in Boston, MA. LY-294002 demonstrated potent PI3K-alpha and mTOR inhibition with Ki values of 350 nM and 1 microM respectively. In an immunohistochemistry study  in liver metastasis and skin biopsies of pancreatic cancer patients, SF-1126 exhibited selectivity towards tumors versus normal tissue [&lt;ulink linkID="1149941" linkType="Reference"&gt;1149941&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2008,  data were presented at the Seventh International Congress on Targeted Therapies in Cancer in Washington DC. SF-1126 inhibited   the PI3K/AKT/mTOR pathway by blocking  VEGF and Bv8 signalling   in  cancer and  endothelial cell lines [&lt;ulink linkID="938201" linkType="Reference"&gt;938201&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2008, preclinical data were reported. Both in vitro and in vivo, SF-1126 showed favorable pharmacokinetics and pharmacodynamic effects as indicated by inhibition of downstream signaling elements. The drug also demonstrated potent antitumor and antiangiogenic activity in vivo, in mouse models, against several human cancer cell types, including prostate, breast, neuroblastoma, and glioblastoma [&lt;ulink linkID="866508" linkType="Reference"&gt;866508&lt;/ulink&gt;], [&lt;ulink linkID="866235" linkType="Reference"&gt;866235&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2007, preclinical data were presented at the 49th ASH meeting in Atlanta, GA. Multiple myeloma cell lines (MM.1R, MM.1S, RPMI 8226) were treated with SF-1126 (1 to 100 microM), dexamethasone (5 microM), &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; (5 microM), &lt;ulink linkID="51717" linkType="Drug"&gt;melphalan&lt;/ulink&gt; (10 microM) alone, and in combination. SF-1126 had IC50 values at 48 h of 8.75 microM and 7.5 microM in the MM.1S and  MM.1R cell lines, respectively. In the MM.1R cell lines, 5 microM SF-1126 alone resulted in 80 and 64% cell viability at 24 and 48 h, respectively. Combination with dexamethasone, melphalan and bortezomib enhanced the efficacy of the drug by 26, 20 and 23%, respectively. Sequential administration of bortezomib and SF-1126 resulted in optimal cell death, with bortezomib administration prior to SF-1126, followed by concurrent administration [&lt;ulink linkID="858214" linkType="Reference"&gt;858214&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, preclinical data were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA. SF-1126 (8 microM) and &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; (8 microM) demonstrated synergistic growth inhibitory activity in PC-3 cells. SF-1126 also demonstrated synergy with doxorubicin against U87MG cells. In vivo, SF-1126 (20 mg/kg iv) plus docetaxel (10 mg/kg iv) showed maximal efficacy against PC-3 prostate cancer xenografts [&lt;ulink linkID="845607" linkType="Reference"&gt;845607&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, preclinical data were presented at the 98th AACR meeting in Los Angeles, CA. In vitro and in vivo studies were carried out to establish the effect of   SF-1126 on renal cancer cell line, 786-0. Western blot analysis of cells treated with SF-1126 (5 and 10 microM) showed that the compound suppressed downstream pathways of PI-3 kinase including p-AKT and p-ERK in the 786-0 cell line and inhibited HIF2a expression.  SF-1126 also significantly inhibit cell migration of  786-0 cells. In vivo, SF-1126 (25 mg/kg/dose 3 x week for  3 weeks)   resulted in inhibition   of tumor growth by  &amp;gt; 95% by day 42 as well as exhibiting potent antiangiogenic activity by  reducing the number of microvessels in xenograft mouse models [&lt;ulink linkID="783161" linkType="Reference"&gt;783161&lt;/ulink&gt;]. Further data were presented in April 2007 on the in vitro effects of SF-1126 in combination with doxorubicin on  a subset of neuroblastoma (NB) cell lines containing  wild type (wt) p53  ( SH-SY5Y, SKBE(1) and NB-1691) and an NB cell line containing mutant p53  (NB-EB). SF-1126 was shown to significantly enhance chemosensitivity at lower pharmacological levels of doxorubicin,  reduce phosphorylation of Akt and constitutively elevate pMdm2 in a dose and early time course dependent manner in p53 wt cell lines. In NB-EB cells, SF-1126 was unable to sensitize cells at  lower levels of doxorubicin  due to the loss of p53 function.    Immunoblotting analysis also showed that SF-1126 inhibited IGF-1 induced Akt phosphorylation at 1 and 24 h. In vivo, SF-2611 was shown to inhibit tumor growth in a  NB  cell line  xenograft model [&lt;ulink linkID="786826" linkType="Reference"&gt;786826&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In December 2006, preclinical data were presented at the 48th ASH meeting in Orlando, FL. Growth of MM.1S and MM.1R cell lines was inhibited following SF-1126 treatment, with IC50 values of 7.5 and 10.8 microM, respectively. The IC50 values for inhibition of p-Akt in MM.1S and MM.1R cells were determined to be 2.4 and 2.8 microM, respectively. SF-1126 treatment (50-mg/kg, sc, given every other day) inhibited MM.1R tumor growth in nude mouse xenografts 95% as compared to untreated controls on day 38 (p &amp;lt; 0.01). Microvessel density analysis of MM.1R tumor tissue demonstrated that SF-1126  also had significant antiangiogenic activity in vivo [&lt;ulink linkID="748205" linkType="Reference"&gt;748205&lt;/ulink&gt;], [&lt;ulink linkID="752467" linkType="Reference"&gt;752467&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, preclinical data were presented at SRI's Angiogenesis and Vascular Targeting Agents Conference in Boston, MA. SF-1126 inhibited all isoforms of PI3K (0.5 to 5.7 microM). Conjugation to an RGD peptide (RGD-SF-1126) enabled it to specifically target tumor endothelial cells. The compound demonstrated potent antitumor activity in several xenograft models of brain, prostate, renal cell carcinoma, multiple myeloma, breast carcinoma and colon carcinoma [&lt;ulink linkID="728611" linkType="Reference"&gt;728611&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2004, preclinical data on SF-1126 were presented at the AACR Basic, Translational and Clinical Advances in Prostate Cancer Conference in Bonita Springs, FL. SF-1126 was safe and effective in a preclinical xenograft model of prostate cancer. In the study, SF-1126 inhibited tumor growth by as much as 97% versus control with excellent safety [&lt;ulink linkID="572011" linkType="Reference"&gt;572011&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2004, preclinical data on SF-1126 were presented at the 3rd International Congress on Targeted Therapies in Cancer in Washington, DC.  In a murine model of glioma, SF-1126 was shown to have  antitumor and anti-angiogenic properties [&lt;ulink linkID="556359" linkType="Reference"&gt;556359&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, preclinical data on SF-1126 were presented at the Anticancer Drug Discovery &amp;amp; Development Summit in Philadelphia, PA. Treatment with SF-1126 resulted in tumor reduction in a xenograft mouse model of prostate cancer. The data also demonstrated that Semafore's proprietary targeting modifications had the potential to eliminate the toxicity that occurred with a non-targeted version of the same inhibitor [&lt;ulink linkID="550398" linkType="Reference"&gt;550398&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2004, Semafore reported results from a mouse model of non-small-cell lung cancer, showing that SF-1126 caused a 68% reduction in tumor volume with no significant weight loss, compared to a 49% tumor reduction with significant weight loss for an untargeted PI3K inhibitor. Toxicity for SF-1126 remained low even with a dose that was 37% higher than a fatal dose of the untargeted inhibitor [&lt;ulink linkID="543627" linkType="reference"&gt;543627&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, preclinical data published by ComChem, demonstrated the in vivo efficacy for PI3K inhibitors against brain cancer. The study identified PI3K as a non-redundant intercept cell signaling switch for cell survival, cell proliferation, angiogenesis, and apoptosis, and supported the concept that controlling PI3K with targeted small-molecule drugs could provide significant advantages for therapy of cancer and multiple other disorders [&lt;ulink linkID="506219" linkType="reference"&gt;506219&lt;/ulink&gt;], [&lt;ulink linkID="506112" linkType="reference"&gt;506112&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2006, the Multiple Myeloma Research Foundation gave Semafore   a 2 or 3 year multiple myeloma R&amp;amp;D grant for SF-1126. Semafore received $1 million for a phase I multiple myeloma trial [&lt;ulink linkID="748502" linkType="Reference"&gt;748502&lt;/ulink&gt;], [&lt;ulink linkID="748511" linkType="Reference"&gt;748511&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006, Semafore was awarded a $2.27 million grant to fund phase I solid tumor trials of SF-1126. The trials were to begin later in 2006 [&lt;ulink linkID="656257" linkType="Reference"&gt;656257&lt;/ulink&gt;]. In December 2006, the Cancer Treatment Research Foundation (CTRF) gave Semafore  a grant to support a phase I trial of SF-1126. The study would assess the safety, pharmacokinetics and pharmacodynamics of the drug in relapsed solid cancer patients [&lt;ulink linkID="747721" linkType="Reference"&gt;747721&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2005, &lt;ulink linkID="PA3046115" linkType="Patent"&gt;US-06949537&lt;/ulink&gt; was issued, claiming   SF-1126, and other &lt;ulink linkID="8278" linkType="Drug"&gt;LY-294002&lt;/ulink&gt; prodrugs [&lt;ulink linkID="625532" linkType="Reference"&gt;625532&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="307">Squamous cell carcinoma</Indication><StatusDate>2016-12-13T00:00:00.000Z</StatusDate><Source id="1728115" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2016-12-13T00:00:00.000Z</StatusDate><Source id="1728115" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2013-11-13T00:00:00.000Z</StatusDate><Source id="1499006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2726">Neuroblastoma</Indication><StatusDate>2015-01-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2013-11-13T00:00:00.000Z</StatusDate><Source id="1499006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2013-11-13T00:00:00.000Z</StatusDate><Source id="1499006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2726">Neuroblastoma</Indication><StatusDate>2015-07-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2013-11-13T00:00:00.000Z</StatusDate><Source id="1499006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003729">Semafore Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2013-11-13T00:00:00.000Z</StatusDate><Source id="1499006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003729">Semafore Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2013-11-13T00:00:00.000Z</StatusDate><Source id="1499006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003729">Semafore Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2013-11-13T00:00:00.000Z</StatusDate><Source id="1499006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1003729">Semafore Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2013-11-13T00:00:00.000Z</StatusDate><Source id="1499006" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1003729">Semafore Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2010-02-22T00:00:00.000Z</StatusDate><Source id="1076548" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003729">Semafore Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2010-02-22T00:00:00.000Z</StatusDate><Source id="1076548" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003729">Semafore Pharmaceuticals Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1828">Multiple myeloma</Indication><StatusDate>2008-01-07T00:00:00.000Z</StatusDate><Source id="865394" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003729">Semafore Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2007-03-26T00:00:00.000Z</StatusDate><Source id="777750" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2726">Neuroblastoma</Indication><StatusDate>2015-01-08T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1003729">Semafore Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2003-07-31T00:00:00.000Z</StatusDate><Source id="506219" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1003729">Semafore Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1734">Chronic lymphocytic leukemia</Indication><AwardedIndication>Treatment of chronic lymphocytic leukemia (CLL)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-11-02T00:00:00.000Z</MileStoneDate><Source id="1146514" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01553"><Name>Phosphoinositide 3-kinase</Name><SwissprotNumbers/></Target><Target id="PTGT-01570"><Name>PIM-1 protein kinase</Name><SwissprotNumbers><Swissprot>P06803</Swissprot><Swissprot>P11309</Swissprot><Swissprot>P26794</Swissprot><Swissprot>Q95LJ0</Swissprot><Swissprot>Q9N0P9</Swissprot><Swissprot>Q9YHZ5</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01588"><Name>Polo-like kinase 1</Name><SwissprotNumbers><Swissprot>P34331</Swissprot><Swissprot>P53350</Swissprot><Swissprot>P62205</Swissprot><Swissprot>P70032</Swissprot><Swissprot>Q07832</Swissprot><Swissprot>Q62673</Swissprot></SwissprotNumbers></Target><Target id="PTGT-05364"><Name>DNA dependent protein kinase</Name><SwissprotNumbers><Swissprot>P78527</Swissprot><Swissprot>P97313</Swissprot><Swissprot>Q8QGX4</Swissprot><Swissprot>Q8WN22</Swissprot><Swissprot>Q9DEI1</Swissprot></SwissprotNumbers></Target><Target id="PTGT-13173"><Name>mTOR complex 1</Name><SwissprotNumbers/></Target><Target id="PTGT-13174"><Name>mTOR complex 2</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1003729">Semafore Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="1034444">CancerCare Manitoba Foundation Inc.</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1037297">Multiple Myeloma Research Foundation</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1059679">The Indiana 21st Century Research and Technology Fund</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1087306">SignalRx Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>3</CountActive><CountInactive>0</CountInactive><CountTotal>3</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="124172" title="The MMRF to provide funding to Semafore for SF-1126"/><Deal id="124174" title="The 21st Century Research and Technology Fund to provide funding to Semafore for SF-1126"/><Deal id="124176" title="The CTRF to provide funding to Semafore for SF-1126"/><Deal id="149847" title="SignalRx Pharmaceuticals to obtain rights to Semafore's SF-1126 and SF-2523"/></Deals><PatentFamilies><PatentFamily id="1659144" number="WO-2004089925" title="Pi-3 kinase inhibitor prodrugs"/><PatentFamily id="1827207" number="WO-2009094560" title="Thienopyranones as kinase inhibitors"/><PatentFamily id="2369924" number="WO-2009108704" title="O-alkylated PI-3 kinase inhibitor prodrug combination"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Semafore Pharmaceuticals Inc" id="1003729"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SignalRx Pharmaceuticals Inc" id="1087306"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="61046"><DrugName>monoclonal antibodies (rheumatoid arthritis), SinoMab Bioscience</DrugName><DrugSynonyms><Name><Value>monoclonal antibodies (rheumatoid arthritis), SinoMab Bioscience</Value></Name><Name><Value>mAbs (rheumatoid arthritis), SinoMab Bioscience</Value></Name></DrugSynonyms><CompanyOriginator id="1040621">SinoMab Bioscience Ltd</CompanyOriginator><CompaniesSecondary><Company id="1040621">SinoMab Bioscience Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1040621" type="Company"><TargetEntity id="5035525409" type="organizationId">SinoMab Bioscience Ltd</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="291">Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="51">Monoclonal antibody</Technology></Technologies><LastModificationDate>2011-01-05T10:59:36.000Z</LastModificationDate><ChangeDateLast>2011-01-05T10:59:36.000Z</ChangeDateLast><AddedDate>2008-08-18T12:02:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1040621"&gt;SinoMab Bioscience&lt;/ulink&gt; was investigating a series of monoclonal antibodies (mAbs) for the potential treatment of rheumatoid arthritis [&lt;ulink linkType="Reference" linkID="931780"&gt;931780&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="935070"&gt;935070&lt;/ulink&gt;]. In September 2006, an NDA was filed with the Chinese SFDA through the company's subsidiary, Lonn Ryonn Pharma. At that time, clinical evaluation was expected to begin in late 2007 [&lt;ulink linkType="Reference" linkID="935070"&gt;935070&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1040621">SinoMab Bioscience Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-01-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1040621">SinoMab Bioscience Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2006-09-30T00:00:00.000Z</StatusDate><Source id="931780" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="62583"><DrugName>IDP-73152</DrugName><DrugSynonyms><Name><Value>peptide deformylase inhibitors (bacterial infection), Il Dong</Value></Name><Name><Value>IDP-204040</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IDP-204042</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IDP-73152</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>IDP-73152 mesylate</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17101">Il Dong Pharmaceutical Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17101" type="Company"><TargetEntity id="4295881034" type="organizationId">Ildong Holdings Co Ltd</TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"/><TargetEntity id="10060945" type="MEDDRA"/><TargetEntity id="D001424" type="MeSH"/><TargetEntity id="-1693440076" type="omicsDisease"/><TargetEntity id="800" type="siCondition"/></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity></SourceEntity><SourceEntity id="2968" type="Action"><TargetEntity id="1445" type="Mechanism">Peptide Deformylase (PDF) Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="40">Bacterial infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="2968">Peptide deformylase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1594">Antibacterial</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="66">Antibiotic</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-08-10T15:37:17.000Z</LastModificationDate><ChangeDateLast>2018-08-14T00:00:00.000Z</ChangeDateLast><AddedDate>2009-02-19T18:30:53.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17101" linkType="Company"&gt;Il Dong&lt;/ulink&gt; was developing the antibiotic IDP-73152 (IDP-73152 mesylate), a lead oxazolidinone-based peptide deformylase (PDF) inhibitor, in both oral and iv formulation, for the potential treatment of bacterial  infections [&lt;ulink linkID="943796" linkType="Reference"&gt;943796&lt;/ulink&gt;], [&lt;ulink linkID="1270102" linkType="Reference"&gt;1270102&lt;/ulink&gt;], [&lt;ulink linkID="1288083" linkType="Reference"&gt;1288083&lt;/ulink&gt;], [&lt;ulink linkID="1323141" linkType="Reference"&gt;1323141&lt;/ulink&gt;]. In July 2013, a phase I trial was initiated in  Korea [&lt;ulink linkID="1461659" linkType="Reference"&gt;1461659&lt;/ulink&gt;]; in March 2015, data were presented from this study [&lt;ulink linkID="1639682" linkType="Reference"&gt;1639682&lt;/ulink&gt;], [&lt;ulink linkID="1639021" linkType="Reference"&gt;1639021&lt;/ulink&gt;]. In December 2016, development appeared to be ongoing [&lt;ulink linkID="1916213" linkType="Reference"&gt;1916213&lt;/ulink&gt;]. However, no development has been reported for some time.&lt;/para&gt;&lt;para&gt;The company was previously other peptide deformylase inhibitors, including IDP-204040 and IDP-204042  [&lt;ulink linkID="943796" linkType="Reference"&gt;943796&lt;/ulink&gt;]; however, no further development was reported for these research codes since September 2009.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In February 2009, an undisclosed lead compound was expected to enter the clinic in 2010 [&lt;ulink linkID="985421" linkType="Reference"&gt;985421&lt;/ulink&gt;]; by January 2010, IDP-73152 was scheduled to enter clinical trials in 2011 [&lt;ulink linkID="1089918" linkType="Reference"&gt;1089918&lt;/ulink&gt;]. In February 2012, IDP-73152 was expected to enter phase I development that year [&lt;ulink linkID="1270102" linkType="Reference"&gt;1270102&lt;/ulink&gt;]. By July 2012, the Korean FDA had approved an IND for a phase I trial [&lt;ulink linkID="1319447" linkType="Reference"&gt;1319447&lt;/ulink&gt;]. By August 2012, a phase I trial was to evaluate  pharmacokinetics and tolerability [&lt;ulink linkID="1332952" linkType="Reference"&gt;1332952&lt;/ulink&gt;]. In July 2013, the dose block-randomized, double-blinded, placebo-controlled, single dose, dose-escalation clinical phase I study (&lt;ulink linkID="147176" linkType="Protocol"&gt;NCT01904318&lt;/ulink&gt;; ID-PDF-70-1) to assess the safety and tolerability of IDP-73152 was planned to be initiated in healthy subjects (n = 56) in Korea later that month. At that time, the trial was expected to be completed in January 2014. In July 2013, the trial was initiated and completed in January 2014 [&lt;ulink linkID="1461659" linkType="Reference"&gt;1461659&lt;/ulink&gt;]. In March 2015, data were presented at the 116th ASCPT Annual Meeting in New Orleans, LA. Pharmacokinetic data showed Cmax and AUC values to increase dose-proportionally up to 320 mg. Tmax was delayed and half-life decreased with increased doses. A decrease in systemic exposure of IDP-73152 mesylate 640 mg was observed when the drug was administered with food: Tmax was higher with food. The treatment was well tolerated [&lt;ulink linkID="1639021" linkType="Reference"&gt;1639021&lt;/ulink&gt;], [&lt;ulink linkID="1639682" linkType="Reference"&gt;1639682&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In July 2012, it was reported that non-clinical studies had been completed in 2011. IDP-73152, which inhibits  bacterial protein synthesis, was shown to be active against superbacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) [&lt;ulink linkID="1319447" linkType="Reference"&gt;1319447&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2010, IDP-73152 had been identified as a lead  [&lt;ulink linkID="1089918" linkType="Reference"&gt;1089918&lt;/ulink&gt;]. In June 2012, in vitro data showed that IDP-73152 was superior to other peptide deformylase inhibitors, &lt;ulink linkID="25407" linkType="Drug"&gt;LBM-415&lt;/ulink&gt; and &lt;ulink linkID="62856" linkType="Drug"&gt;GSK-1322322&lt;/ulink&gt; [&lt;ulink linkID="1323141" linkType="Reference"&gt;1323141&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2005, data from in vivo studies of lead compounds, IDP-204040 and IDP-204042, showed that they had promising activity against Enterococcus faecium and Streptococcus pneumoniae [&lt;ulink linkID="943796" linkType="Reference"&gt;943796&lt;/ulink&gt;]. In February 2009, preclinical studies were ongoing [&lt;ulink linkID="985421" linkType="Reference"&gt;985421&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2018-08-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2006-09-05T00:00:00.000Z</StatusDate><Source id="943796" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2013-07-31T00:00:00.000Z</StatusDate><Source id="1461659" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01538"><Name>Peptide deformylase</Name><SwissprotNumbers><Swissprot>O08450</Swissprot><Swissprot>O51092</Swissprot><Swissprot>O66847</Swissprot><Swissprot>O83738</Swissprot><Swissprot>O84357</Swissprot><Swissprot>P0A6K3</Swissprot><Swissprot>P0A6K4</Swissprot><Swissprot>P0A6K5</Swissprot><Swissprot>P43522</Swissprot><Swissprot>P44786</Swissprot><Swissprot>P47352</Swissprot><Swissprot>P56419</Swissprot><Swissprot>P57563</Swissprot><Swissprot>P57948</Swissprot><Swissprot>P59493</Swissprot><Swissprot>P63913</Swissprot><Swissprot>P63914</Swissprot><Swissprot>P63915</Swissprot><Swissprot>P63916</Swissprot><Swissprot>P63917</Swissprot><Swissprot>P63918</Swissprot><Swissprot>P68771</Swissprot><Swissprot>P68825</Swissprot><Swissprot>P68826</Swissprot><Swissprot>P73441</Swissprot><Swissprot>P75527</Swissprot><Swissprot>P94601</Swissprot><Swissprot>P96113</Swissprot><Swissprot>P99077</Swissprot><Swissprot>Q48661</Swissprot><Swissprot>Q5HGZ3</Swissprot><Swissprot>Q5HQ78</Swissprot><Swissprot>Q5X9V1</Swissprot><Swissprot>Q6GAC3</Swissprot><Swissprot>Q6GHZ4</Swissprot><Swissprot>Q721B5</Swissprot><Swissprot>Q72S74</Swissprot><Swissprot>Q7M7M2</Swissprot><Swissprot>Q7MT07</Swissprot><Swissprot>Q7MYI2</Swissprot><Swissprot>Q7NAK8</Swissprot><Swissprot>Q7NQ75</Swissprot><Swissprot>Q7U206</Swissprot><Swissprot>Q7U9D4</Swissprot><Swissprot>Q7UHZ5</Swissprot><Swissprot>Q7V3K7</Swissprot><Swissprot>Q7VED2</Swissprot><Swissprot>Q7VIN5</Swissprot><Swissprot>Q7VKK9</Swissprot><Swissprot>Q7VQC0</Swissprot><Swissprot>Q823U4</Swissprot><Swissprot>Q82ZJ0</Swissprot><Swissprot>Q83GH8</Swissprot><Swissprot>Q83HQ3</Swissprot><Swissprot>Q83PZ1</Swissprot><Swissprot>Q88VB2</Swissprot><Swissprot>Q895Q2</Swissprot><Swissprot>Q89BN9</Swissprot><Swissprot>Q8AAP4</Swissprot><Swissprot>Q8CPN4</Swissprot><Swissprot>Q8D258</Swissprot><Swissprot>Q8DIB4</Swissprot><Swissprot>Q8DP79</Swissprot><Swissprot>Q8DWC2</Swissprot><Swissprot>Q8DXF6</Swissprot><Swissprot>Q8E378</Swissprot><Swissprot>Q8ER96</Swissprot><Swissprot>Q8EVJ8</Swissprot><Swissprot>Q8K975</Swissprot><Swissprot>Q8KCG7</Swissprot><Swissprot>Q8NX78</Swissprot><Swissprot>Q8NZB7</Swissprot><Swissprot>Q8R9T0</Swissprot><Swissprot>Q8REF0</Swissprot><Swissprot>Q8UID1</Swissprot><Swissprot>Q8Y866</Swissprot><Swissprot>Q8Z1W9</Swissprot><Swissprot>Q8ZJ79</Swissprot><Swissprot>Q8ZLM7</Swissprot><Swissprot>Q92CX8</Swissprot><Swissprot>Q92SH6</Swissprot><Swissprot>Q93LE9</Swissprot><Swissprot>Q98D52</Swissprot><Swissprot>Q98PN3</Swissprot><Swissprot>Q9ABF5</Swissprot><Swissprot>Q9CBI2</Swissprot><Swissprot>Q9F2F0</Swissprot><Swissprot>Q9I7A8</Swissprot><Swissprot>Q9K9I9</Swissprot><Swissprot>Q9PIT8</Swissprot><Swissprot>Q9PK41</Swissprot><Swissprot>Q9PQ25</Swissprot><Swissprot>Q9RRQ4</Swissprot><Swissprot>Q9Z6J2</Swissprot><Swissprot>Q9ZDV8</Swissprot><Swissprot>Q9ZL51</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17101">Il Dong Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28971">Republic of Korea Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="141334" title="Korean MKE to financially support development of Il Dong's IDP-73152"/></Deals><PatentFamilies><PatentFamily id="1291568" number="WO-2006115353" title="A novel hydroxamic acid derivative as peptide deformylase inhibitor and manufacturing method thereof"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Il Dong Pharmaceutical Co Ltd" id="17101"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="64635"><DrugName>LIM-0741</DrugName><DrugSynonyms><Name><Value>LIM-0741</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1021109">Limerick BioPharma Inc</CompanyOriginator><CompaniesSecondary><Company id="1021109">Limerick BioPharma Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="64635" type="Drug"><TargetEntity id="677398" type="siDrug">LIM-0741</TargetEntity></SourceEntity><SourceEntity id="1021109" type="Company"><TargetEntity id="4297528833" type="organizationId">Limerick BioPharma Inc</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="735">Toxicity</Indication></IndicationsSecondary><ActionsPrimary><Action id="8127">Unspecified transporter protein stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="959">Protectant</Action></ActionsSecondary><Technologies><Technology id="603">Systemic formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2010-05-24T15:22:13.000Z</LastModificationDate><ChangeDateLast>2010-05-24T15:22:13.000Z</ChangeDateLast><AddedDate>2009-10-16T13:17:27.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1021109"&gt;Limerick BioPharma&lt;/ulink&gt;  was developing LIM-0741, a cellular transport activator, for the potential prevention of side effects associated with analgesic treatment.   By March 2009, the drug was   listed as being in phase I on the company pipeline [&lt;ulink linkType="Reference" linkID="995044"&gt;995044&lt;/ulink&gt;].  By May 2010, the drug was no longer listed on the company's pipeline and development was presumed to have been discontinued [&lt;ulink linkType="Reference" linkID="1102648"&gt;1102648&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1021109">Limerick BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="735">Toxicity</Indication><StatusDate>2010-05-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1021109">Limerick BioPharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="735">Toxicity</Indication><StatusDate>2009-03-26T00:00:00.000Z</StatusDate><Source id="995044" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-09767"><Name>Unspecified transporter protein</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="69555"><DrugName>anticancer antibodies, CSL/Patrys</DrugName><DrugSynonyms><Name><Value>anticancer antibodies, CSL/Patrys</Value></Name><Name><Value>PAT-CSL1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PAT-CSL2</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PAT-CSL3</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PAT-CSL4</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1034206">Patrys Ltd</CompanyOriginator><CompaniesSecondary><Company id="1034206">Patrys Ltd</Company><Company id="15563">CSL Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1034206" type="Company"><TargetEntity id="4295858654" type="organizationId">Patrys Ltd</TargetEntity></SourceEntity><SourceEntity id="15563" type="Company"><TargetEntity id="4295856855" type="organizationId">CSL Ltd</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="55684" type="Action"><TargetEntity id="3993" type="Mechanism">Anti-Stage-Specific Embryonic Antigen (SSEA)-5 (Anti-H Type-1 Antigen)</TargetEntity><TargetEntity id="3294" type="Mechanism">Drugs Targeting Cancer Associated Antigens</TargetEntity><TargetEntity id="3601" type="Mechanism">Anti-Tn Antigen</TargetEntity><TargetEntity id="3131" type="Mechanism">Anti-Thomsen-Friedenreich Antigen (CD176)</TargetEntity><TargetEntity id="4126" type="Mechanism">Anti-Globo H</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="55684">Anticancer antibody</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="1">Antibody</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2017-07-25T10:32:47.000Z</LastModificationDate><ChangeDateLast>2017-07-27T00:00:00.000Z</ChangeDateLast><AddedDate>2011-01-04T06:15:05.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1034206" linkType="Company"&gt;Patrys&lt;/ulink&gt;  and &lt;ulink linkID="15563" linkType="Company"&gt;CSL&lt;/ulink&gt; were co-investigating a series of  antibodies, including PAT-CSL1, PAT-CSL2, PAT-CSL3, and PAT-CSL4, for the potential treatment of cancer [&lt;ulink linkID="1071284" linkType="Reference"&gt;1071284&lt;/ulink&gt;], [&lt;ulink linkID="1104145" linkType="Reference"&gt;1104145&lt;/ulink&gt;], [&lt;ulink linkID="1158541" linkType="Reference"&gt;1158541&lt;/ulink&gt;]. By January 2011, preclinical studies were still ongoing [&lt;ulink linkID="866252" linkType="Reference"&gt;1158541&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt; By January 2011,  all the compounds had shown the ability to kill  cancer cells.   PAT-CSL1, PAT-CSL2 and PAT-CSL3 had demonstrated  efficacy    in animal models of cancer and was expected to be demonstrated in   PAT-CSL4 during 2010.  By January 2011, the specific target   for  PAT-CSL1 had been determined, and was due to be  determined for rest of the compounds   in 2010 [&lt;ulink linkID="1158541" linkType="Reference"&gt;1158541&lt;/ulink&gt;]&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1034206">Patrys Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2012-12-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15563">CSL Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2012-12-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1034206">Patrys Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2010-01-28T00:00:00.000Z</StatusDate><Source id="1071284" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15563">CSL Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2010-01-28T00:00:00.000Z</StatusDate><Source id="1071284" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1034206">Patrys Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15563">CSL Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="129396" title="CSL to research and develop certain early-stage antibodies from Patrys"/></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="76924"><DrugName>peptide-based HIV-1 intergrase protein interaction inhibitor (HIV), Genoscience</DrugName><DrugSynonyms><Name><Value>Pc1l</Value></Name><Name><Value>peptide-based HIV-1 intergrase protein interaction inhibitor (HIV), Genoscience</Value></Name></DrugSynonyms><CompanyOriginator id="1007786">Genoscience</CompanyOriginator><CompaniesSecondary><Company id="1007786">Genoscience</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1007786" type="Company"><TargetEntity id="4297914598" type="organizationId">Genoscience Pharma SAS</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"/><TargetEntity id="042" type="ICD9"/><TargetEntity id="10020161" type="MEDDRA"/><TargetEntity id="D015658" type="MeSH"/><TargetEntity id="-841965209" type="omicsDisease"/><TargetEntity id="862" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="158">HIV infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="7588">HIV-1 integrase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2014-03-26T10:20:21.000Z</LastModificationDate><ChangeDateLast>2014-04-09T00:00:00.000Z</ChangeDateLast><AddedDate>2012-03-31T05:07:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1007786"&gt;Genoscience&lt;/ulink&gt; was investigating a series of short peptides derived from HIV-1 reverse transcriptase, including Pc1l,  to target HIV-1 integrase interactions for the potential treatment of HIV infection. In March 2012, development of the drug was ongoing [&lt;ulink linkType="Reference" linkID="1273047"&gt;1273047&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2012,  data on the 11-mer cyclic peptide Pc1l were presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, WA, USA. Pc1l  was shown to disrupt the association of HIV-1 intergrase with DNA, HIV-1 reverse transcriptase and lens epithelium-derived growth factor  at nanomolar concentrations, and demonstrated potent anti-HIV activity in a Pep-1 nanoparticle complex (IC50 = 0.3 nM). Activity was demonstrated against all HIV-1 subtypes with IC50 values ranging from 5 to 0.7 nM. No Pc1l-resistant strains were identified during a 12-month evaluation [&lt;ulink linkType="Reference" linkID="1273047"&gt;1273047&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1007786">Genoscience</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>2014-03-26T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1007786">Genoscience</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>2012-03-07T00:00:00.000Z</StatusDate><Source id="1273047" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00938"><Name>HIV-1 integrase</Name><SwissprotNumbers><Swissprot>P03366</Swissprot><Swissprot>P03367</Swissprot><Swissprot>P03369</Swissprot><Swissprot>P04585</Swissprot><Swissprot>P04586</Swissprot><Swissprot>P04587</Swissprot><Swissprot>P04588</Swissprot><Swissprot>P04589</Swissprot><Swissprot>P05959</Swissprot><Swissprot>P05960</Swissprot><Swissprot>P05961</Swissprot><Swissprot>P12497</Swissprot><Swissprot>P12498</Swissprot><Swissprot>P12499</Swissprot><Swissprot>P18802</Swissprot><Swissprot>P20875</Swissprot><Swissprot>P20892</Swissprot><Swissprot>P24740</Swissprot><Swissprot>P35963</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="82151"><DrugName>Lanthi-apelin</DrugName><DrugSynonyms><Name><Value>lanthionine-stabilized apelin receptor agonist (diabetes), Lanthio Pharma</Value></Name><Name><Value>LP-7</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>lanthionine-stabilized apelin receptor agonist (heart failure), Lanthio Pharma</Value></Name><Name><Value>Lanthi-apelin</Value></Name></DrugSynonyms><CompanyOriginator id="1066499">Lanthio Pharma</CompanyOriginator><CompaniesPrimary><Company id="1066499">Lanthio Pharma</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1066499" type="Company"><TargetEntity id="5037136089" type="organizationId">Lanthiopep BV</TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"/><TargetEntity id="10007554" type="MEDDRA"/><TargetEntity id="D006333" type="MeSH"/><TargetEntity id="-1323949873" type="omicsDisease"/><TargetEntity id="237" type="siCondition"/></SourceEntity><SourceEntity id="97" type="ciIndication"><TargetEntity id="10012601" type="MEDDRA"/><TargetEntity id="D003920" type="MeSH"/><TargetEntity id="-203480060" type="omicsDisease"/><TargetEntity id="506" type="siCondition"/></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="10888" type="Action"><TargetEntity id="4801" type="Mechanism">Apelin Receptor (Angiotensin-Receptor Like 1; APJ) Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-02614" type="ciTarget"><TargetEntity id="12087520201873" type="siTarget">Apelin receptor</TargetEntity><TargetEntity id="-806222542" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="55">Cardiac failure</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="97">Diabetes mellitus</Indication></IndicationsSecondary><ActionsPrimary><Action id="10888">Apelin receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="80">Peptide</Technology></Technologies><EphmraCodes><Ephmra><Code>A10</Code><Name>DRUGS USED IN DIABETES</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-24T07:53:27.000Z</LastModificationDate><ChangeDateLast>2017-06-23T00:00:00.000Z</ChangeDateLast><AddedDate>2012-12-04T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1066499" linkType="Company"&gt;Lanthio&lt;/ulink&gt;, a subsidiary of    &lt;ulink linkID="21404" linkType="Company"&gt;MorphoSys&lt;/ulink&gt;, is investigating  	 Lanthi-apelin (LP-7), a  lanthionine-stabilized   version of apelin, the endogenous peptide agonist ligand for the G-protein-coupled APJ receptor, for the potential treatment of heart failure. In August  2014, the peptide was listed as being in discovery [&lt;ulink linkID="1587074" linkType="Reference"&gt;1587074&lt;/ulink&gt;], [&lt;ulink linkID="1658443" linkType="Reference"&gt;1658443&lt;/ulink&gt;]. In June 2017, the peptide was listed on the company's pipeline [&lt;ulink linkID="1940187" linkType="Reference"&gt;1940187&lt;/ulink&gt;]. In November 2012, Lanthio was seeking to outlicense  the program  [&lt;ulink linkID="1345711" linkType="Reference"&gt;1345711&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Lanthio was previously investigating LP-7,  for the potential treatment of diabetes. However, in January 2014, this indication was no longer listed on the company's development pipeline [&lt;ulink linkID="1345711" linkType="Reference"&gt;1345711&lt;/ulink&gt;], [&lt;ulink linkID="1345713" linkType="Reference"&gt;1345713&lt;/ulink&gt;], [&lt;ulink linkID="1514553" linkType="Reference"&gt;1514553&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1066499">Lanthio Pharma</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="55">Cardiac failure</Indication><StatusDate>2014-01-10T00:00:00.000Z</StatusDate><Source id="1514553" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1066499">Lanthio Pharma</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="97">Diabetes mellitus</Indication><StatusDate>2014-01-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1066499">Lanthio Pharma</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="97">Diabetes mellitus</Indication><StatusDate>2012-11-14T00:00:00.000Z</StatusDate><Source id="1345713" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-02614"><Name>Apelin receptor</Name><SwissprotNumbers><Swissprot>O97666</Swissprot><Swissprot>P35414</Swissprot><Swissprot>Q9JHG3</Swissprot><Swissprot>Q9WV08</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1940187" linkType="reference" linkID="1940187"&gt;1940187&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="3038619" number="WO-2015147641" title="Cyclic apelin analogs"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="MorphoSys AG" id="21404"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="87316"><DrugName>Rab38 (50 to 58) peptide/Montanide ISA-51 vaccine (malignant melanoma), University of Heidelberg</DrugName><DrugSynonyms><Name><Value>Rab38 (50 to 58) peptide/Montanide ISA-51 vaccine (malignant melanoma), University of Heidelberg</Value></Name><Name><Value>NY-MEL-1 (50 to 58) peptide/Montanide ISA-51 vaccine (malignant melanoma), University of Heidelberg</Value></Name></DrugSynonyms><CompanyOriginator id="28348">University of Heidelberg</CompanyOriginator><CompaniesSecondary><Company id="28348">University of Heidelberg</Company></CompaniesSecondary><CrossReferences><SourceEntity id="28348" type="Company"><TargetEntity id="5035524090" type="organizationId">Heidelberg University</TargetEntity></SourceEntity><SourceEntity id="3256" type="ciIndication"><TargetEntity id="10025670" type="MEDDRA"/></SourceEntity><SourceEntity id="3257" type="ciIndication"><TargetEntity id="10027480" type="MEDDRA"/><TargetEntity id="708" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-05798" type="ciTarget"><TargetEntity id="1671556267236823" type="siTarget">Ras-related protein Rab-38</TargetEntity><TargetEntity id="-1770988898" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="3256">Stage III melanoma</Indication><Indication id="3257">Stage IV melanoma</Indication></IndicationsSecondary><ActionsPrimary><Action id="28799">Ras-related protein Rab 38 modulator</Action></ActionsPrimary><ActionsSecondary><Action id="12372">Protein subunit vaccine</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="80">Peptide</Technology></Technologies><LastModificationDate>2014-07-25T10:49:47.000Z</LastModificationDate><ChangeDateLast>2013-09-06T00:00:00.000Z</ChangeDateLast><AddedDate>2013-09-06T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;The &lt;ulink linkType="Company" linkID="28348"&gt;University of Heidelberg&lt;/ulink&gt; was developing Rab38 (50 to 58) peptide vaccine, using Montanide ISA-51 as an adjuvant for the potential prevention or treatment of stage III/IV malignant melanoma. In July 2008, a phase I trial was initiated in patients with  stage III/IV malignant melanoma. In June 2009, the trial was completed [&lt;ulink linkType="Reference" linkID="1404904"&gt;1404904&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In July 2008, an open-label, single-arm, phase I trial (&lt;ulink linkType="Protocol" linkID="121229"&gt;ISRCTN21224989&lt;/ulink&gt;) was initiated in patients (n = 9) with  stage III/IV malignant melanoma in Germany. In June 2009, the trial was completed  [&lt;ulink linkType="Reference" linkID="1404904"&gt;1404904&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28348">University of Heidelberg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2013-09-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28348">University of Heidelberg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate>2013-09-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28348">University of Heidelberg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3256">Stage III melanoma</Indication><StatusDate>2007-07-01T00:00:00.000Z</StatusDate><Source id="1404904" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28348">University of Heidelberg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2007-07-01T00:00:00.000Z</StatusDate><Source id="1404904" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-05798"><Name>Ras-related protein Rab 38</Name><SwissprotNumbers><Swissprot>P57729</Swissprot><Swissprot>Q8QZZ8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="8885"><DrugName>BTG-USA-180973</DrugName><DrugSynonyms><Name><Value>BTG-USA-180973</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>antifungal agent, BTG</Value></Name></DrugSynonyms><CompanyOriginator id="15266">BTG plc</CompanyOriginator><CompaniesSecondary><Company id="15266">BTG plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="15266" type="Company"><TargetEntity id="4295894524" type="organizationId">BTG PLC</TargetEntity></SourceEntity><SourceEntity id="124" type="ciIndication"><TargetEntity id="10017533" type="MEDDRA"/><TargetEntity id="D009181" type="MeSH"/><TargetEntity id="-2109353222" type="omicsDisease"/><TargetEntity id="817" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="124">Fungal infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="2956">Fungal cell wall synthesis inhibitor</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2002-05-29T20:19:47.000Z</LastModificationDate><ChangeDateLast>2002-05-29T20:19:47.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="8885"&gt;BTG-USA-180973&lt;/ulink&gt; is a potential antifungal agent which was being investigated by British Technology Group [&lt;ulink linkType="reference" linkID="179810"&gt;179810&lt;/ulink&gt;]. However, no development has been reported since 1995 [&lt;ulink linkType="reference" linkID="179810"&gt;179810&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound is an alpha-stryl-carbonyl derivative which was both orally and parenterally effective as a broad-spectrum antifungal in various in vitro and in vivo models. The agent was thought to act upon fungal permeases, involved in the transport of peptides across cell walls [&lt;ulink linkType="reference" linkID="168568"&gt;168568&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15266">BTG plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>2001-06-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15266">BTG plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>1995-03-01T00:00:00.000Z</StatusDate><Source id="179810" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="89697"><DrugName>antitrypanosomal compounds (Chagas disease), Sanofi</DrugName><DrugSynonyms><Name><Value>antitrypanosomal compounds (Chagas disease), Sanofi</Value></Name><Name><Value>NEU-321</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1009547">Sanofi SA</CompanyOriginator><CompaniesSecondary><Company id="1009547">Sanofi SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="335" type="ciIndication"><TargetEntity id="B57" type="ICD10"/><TargetEntity id="D014355" type="MeSH"/><TargetEntity id="-1708981827" type="omicsDisease"/><TargetEntity id="1599" type="siCondition"/></SourceEntity><SourceEntity id="2638" type="Action"><TargetEntity id="4622" type="Mechanism">Drugs Targeting Plasmodium falciparum Proteins</TargetEntity><TargetEntity id="4959" type="Mechanism">Drugs Targeting Parasite Proteins</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="335">Trypanosoma cruzi infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="2638">Antiparasitic</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>P</Code><Name>PARASITOLOGY</Name></Ephmra></EphmraCodes><LastModificationDate>2015-11-25T00:56:31.000Z</LastModificationDate><ChangeDateLast>2018-11-13T00:00:00.000Z</ChangeDateLast><AddedDate>2014-01-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt; was investigating imidazole-based compounds, including NEU-321 (structure shown), as potent antitrypanosomal agents for the potential treatment of Chagas                                                    disease [&lt;ulink linkID="1515984" linkType="Reference"&gt;1515984&lt;/ulink&gt;]. By January 2013, preclinical studies were ongoing [&lt;ulink linkID="1515984" linkType="Reference"&gt;1515984&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By January 2013, a series of imidazole-based  compounds  had been synthesized and evaluated as  antitrypanosomal agents. The most potent compound, NEU-321, exhibited activity against Trypanosomal cruzi with an EC50 value of 0.08 microM  and showed good microsomal stability in human, rat and mouse microsomes [&lt;ulink linkID="1515984" linkType="Reference"&gt;1515984&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2015-11-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2013-01-03T00:00:00.000Z</StatusDate><Source id="1515984" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>Cc1cc(cc(c1Cl)C)Oc2cccc(c2)Cn3ccnc3</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug><Drug id="89772"><DrugName>dual adenosine A2A antagonist/MAO-B inhibitors (neurological diseases),Sigma Tau</DrugName><DrugSynonyms><Name><Value>dual adenosine A2A antagonist/MAO-B inhibitors (neurological diseases),Sigma Tau</Value></Name><Name><Value>ST-3564</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="21159">Sigma-Tau Ind Farm Riunite SpA</CompanyOriginator><CompaniesSecondary><Company id="21159">Sigma-Tau Ind Farm Riunite SpA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="21159" type="Company"><TargetEntity id="5035524732" type="organizationId">Sigma-Tau Industrie Farmaceutiche Riunite SpA</TargetEntity></SourceEntity><SourceEntity id="677" type="ciIndication"><TargetEntity id="D009422" type="MeSH"/><TargetEntity id="-482975406" type="omicsDisease"/><TargetEntity id="82" type="siCondition"/></SourceEntity><SourceEntity id="596" type="Action"><TargetEntity id="5117" type="Mechanism">Anti-Adenosine Receptor A2a (ADORA2A)</TargetEntity><TargetEntity id="24" type="Mechanism">Adenosine A2A Antagonists</TargetEntity></SourceEntity><SourceEntity id="255" type="Action"><TargetEntity id="450" type="Mechanism">MAO-B Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00057" type="ciTarget"><TargetEntity id="20140967021353" type="siTarget">Adenosine receptor A2a</TargetEntity><TargetEntity id="8156" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01274" type="ciTarget"><TargetEntity id="56692312941293" type="siTarget">Amine oxidase [flavin-containing] B</TargetEntity><TargetEntity id="6224" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="677">Neurological disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="255">MAO B inhibitor</Action><Action id="596">Adenosine A2a receptor antagonist</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2014-07-14T10:01:14.000Z</LastModificationDate><ChangeDateLast>2014-07-14T00:00:00.000Z</ChangeDateLast><AddedDate>2014-01-21T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="21159"&gt;Sigma Tau&lt;/ulink&gt; was investigating dual adenosine A2A antagonist/ MAO-B inhibitors, including  ST-3564 (structure shown)  for the potential treatment of neurological diseases [&lt;ulink linkType="Reference" linkID="1517036"&gt;1517036&lt;/ulink&gt;]. By November 2012, preclinical studies were ongoing [&lt;ulink linkType="Reference" linkID="1517036"&gt;1517036&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By November 2012, a series of (E)-8-(3-chlorostyryl) caffeine analogs were synthesized and evaluated as dual adenosine A2A antagonist/ MAO-B inhibitors.  ST-3564, the most potent compound had high affinity towards adenosine A2A with Ki value of 260 nM. The representative compound showed IC50 values of 200 and 10000 nM against MAO-B and MOA-A, respectively [&lt;ulink linkType="Reference" linkID="1517036"&gt;1517036&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="21159">Sigma-Tau Ind Farm Riunite SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="677">Neurological disease</Indication><StatusDate>2014-05-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21159">Sigma-Tau Ind Farm Riunite SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="677">Neurological disease</Indication><StatusDate>2012-11-15T00:00:00.000Z</StatusDate><Source id="1517036" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00057"><Name>Adenosine A2a receptor</Name><SwissprotNumbers><Swissprot>P11617</Swissprot><Swissprot>P29274</Swissprot><Swissprot>P30543</Swissprot><Swissprot>P46616</Swissprot><Swissprot>Q60613</Swissprot><Swissprot>Q6TLI7</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01274"><Name>MAO B</Name><SwissprotNumbers><Swissprot>P19643</Swissprot><Swissprot>P27338</Swissprot><Swissprot>P56560</Swissprot><Swissprot>P58028</Swissprot><Swissprot>Q5RE98</Swissprot><Swissprot>Q6PLK3</Swissprot><Swissprot>Q7YRB7</Swissprot><Swissprot>Q8BW75</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>Cn1c(nc2c1c(=O)n(c(=O)n2C)C)/C=C/c3ccc(cc3)Cl</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug><Drug id="90589"><DrugName>Keap1/Nrf2 protein-protein inhibitors (kidney disease), Otsuka</DrugName><DrugSynonyms><Name><Value>ML-334</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Keap1/Nrf2 protein-protein inhibitors (kidney disease), Otsuka</Value></Name><Name><Value>Kelch-like erythroid-cell-derived protein 1/nuclear factor-like 2 protein-protein inhibitors (kidney disease), Otsuka</Value></Name><Name><Value>LH-601A</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1038256">EN Otsuka Pharmaceutical Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="1038256">EN Otsuka Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1038256" type="Company"><TargetEntity id="4298181067" type="organizationId">EN Otsuka Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="286" type="ciIndication"><TargetEntity id="10029151" type="MEDDRA"/><TargetEntity id="D007674" type="MeSH"/><TargetEntity id="-966472843" type="omicsDisease"/><TargetEntity id="334" type="siCondition"/></SourceEntity><SourceEntity id="PTGT-08848" type="ciTarget"><TargetEntity id="110005819498173" type="siTarget">Kelch-like ECH-associated protein 1</TargetEntity><TargetEntity id="2930" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="286">Renal disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="48831">Kelch like ECH associated protein 1 inhibitor</Action><Action id="19502">Nuclear erythroid 2-related factor inhibitor</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2015-11-13T17:03:19.000Z</LastModificationDate><ChangeDateLast>2015-11-17T00:00:00.000Z</ChangeDateLast><AddedDate>2014-04-09T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="21153"&gt;Otsuka&lt;/ulink&gt; is investigating direct Kelch-like erythroid-cell-derived protein 1 (Keap1)/nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein-protein interaction inhibitors, including LH-601A (ML-334; structure shown), for the potential treatment of kidney injury. In March 2014, preclinical data were presented [&lt;ulink linkType="Reference" linkID="1531705"&gt;1531705&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2014, preclinical data were presented at the 55th Annual SOT Meeting and ToxExpo in Phoenix, AZ. Both LH-610A and sulforaphane (an indirect Nrf2 activator/control) upregulated heme oxygenase 1 mRNA and protein expression and thioredoxin-1 mRNA [&lt;ulink linkType="Reference" linkID="1531705"&gt;1531705&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By October 2013, LH-610A was shown to be a promising lead [&lt;ulink linkType="Reference" linkID="1540461"&gt;1540461&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1038256">EN Otsuka Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="286">Renal disease</Indication><StatusDate>2015-11-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1038256">EN Otsuka Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="286">Renal disease</Indication><StatusDate>2013-10-15T00:00:00.000Z</StatusDate><Source id="1540461" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-04574"><Name>Nuclear erythroid 2-related factor</Name><SwissprotNumbers/></Target><Target id="PTGT-08848"><Name>Kelch like ECH associated protein 1</Name><SwissprotNumbers><Swissprot>P57790</Swissprot><Swissprot>Q14145</Swissprot><Swissprot>Q5R774</Swissprot><Swissprot>Q684M4</Swissprot><Swissprot>Q9Z2X8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1ccc2c(c1)CCN([C@@H]2CN3C(=O)c4ccccc4C3=O)C(=O)[C@@H]5CCCC[C@@H]5C(=O)O</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug><Drug id="91141"><DrugName>SCI-RPC-2011</DrugName><DrugSynonyms><Name><Value>SCI-RPC-2011</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1063791">SinoVeda Canada Inc</CompanyOriginator><CompaniesSecondary><Company id="1063791">SinoVeda Canada Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1063791" type="Company"><TargetEntity id="5000461486" type="organizationId">SinoVeda Canada Inc</TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"/><TargetEntity id="D002318" type="MeSH"/><TargetEntity id="-1500764314" type="omicsDisease"/><TargetEntity id="182" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="57">Cardiovascular disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="2659">Cardioprotectant</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C</Code><Name>CARDIOVASCULAR SYSTEM</Name></Ephmra></EphmraCodes><LastModificationDate>2014-05-22T09:25:51.000Z</LastModificationDate><ChangeDateLast>2014-05-22T00:00:00.000Z</ChangeDateLast><AddedDate>2014-05-07T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1063791"&gt;SinoVeda&lt;/ulink&gt; was investigating SCI-RPC-2011, a plant-derived drug candidate, for the potential treatment of cardiovascular diseases [&lt;ulink linkType="Reference" linkID="1278005"&gt;1278005&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1278006"&gt;1278006&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1553770"&gt;1553770&lt;/ulink&gt;]. In February 2012, the drug was listed as being in preclinical development  [&lt;ulink linkType="Reference" linkID="1278005"&gt;1278005&lt;/ulink&gt;]; in February 2013, this was still the case [&lt;ulink linkType="Reference" linkID="1553770"&gt;1553770&lt;/ulink&gt;]. In February 2012, the company was seeking to outlicense the drug [&lt;ulink linkType="Reference" linkID="1278005"&gt;1278005&lt;/ulink&gt;]. However, in May 2014, the program was no longer listed on the company's development pipeline [&lt;ulink linkType="Reference" linkID="1553764"&gt;1553764&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1063791">SinoVeda Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2014-05-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1063791">SinoVeda Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2012-02-28T00:00:00.000Z</StatusDate><Source id="1278005" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>